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Summary and Project Aims 
Andrographolide (ADO) is one of the many active components of the traditional herb 
Andrographis paniculata, which has been extensively used in various forms of 
Ayruvedic and Chinese Medicine. It is a highly versatile compound and has effects on 
different systems. The most well-known effect of ADO to date is its anti-
inflammatory effect due to its ability to inhibit NF-κB activation, and it has been 
shown to alleviate the effects of many inflammatory diseases. However, the cellular 
mechanism of ADO has not yet been fully elucidated, and hence the purpose of this 
project is to elucidate the mechanism through which ADO exerts its various effects. 
 
The first part of the project focuses on the effect ADO has on receptor trafficking, 
using the epidermal growth factor receptor (EGFR) and the transferrin receptor (TfR) 
in the A-431 epidermoid carcinoma cell model. As ADO has been shown to affect the 
expression of surface receptors such as MHC class II, CD40 and CD86 in dendritic 
cells, we hypothesised that ADO could affect endocytic trafficking of receptors. We 
hoped to identify the endocytic pathways that ADO perturbs using EGFR as a model 
receptor that is degraded after internalisation, and TfR as a model receptor that 
constitutively recycles. For the first part of the project, we established that ADO 
downregulates EGFR surface expression by enhancing the endocytosis of EGFRs, and 
endocytosed EGFRs accumulate at the VAMP-8 and LAMP-1 positive late 
endosomes.  
 
The second part of the project seeks to elucidate the molecular mechanism of how 
ADO increases EGFR endocytosis and how ADO effect on EGFR trafficking may 





affect its down-stream mitogen activated protein kinase (MAPK) signalling pathways 
and thus affect cell proliferation. We demonstrate that ADO is able to activate the p38 
MAPK, which then phosphorylates EGFR at the serine 1046/1047 residue, inducing 
its internalisation from the cell surface. 
 
The third part of the project seeks to apply the information we have gained from the 
A-431 epidermoid carcinoma model in an immune cell model to investigate if the 
anti-inflammatory effect from ADO could also be mediated through affecting surface 
expression of immune receptors. We chose to focus on scavenger receptors, which are 
known to be important for bacterial binding, and phagocytic uptake by microglia cells 
of the brain. Phagocytic uptake of bacteria in the brain may potentially induce 
immune activation and causes inflammation of the brain. In this study, we found that 
ADO inhibits phagocytosis through downregulating surface scavenger receptor 
CD204 in microglia. This presents a novel mechanism by which ADO could possibly 
exert its anti-inflammatory effect in the brain. 
 
The results in this study demonstrate an approach to understand the effects of a 
pharmacophore with a known mechanism on other cellular mechanisms, with a 
particular focus on receptors, which are important for mediating the cellular response 








EEA-1 Early endosomal antigen-1 
EGFR Epidermal growth factor receptor 
ERK Extracellular signal regulated kinase 
FACS Fluorescence activated cell sorting 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IFN-γ Interferon gamma 
JNK c-Jun-N-terminal kinase 
LAMP-1 Lysosomal associated membrane protein-1 
LPS Lipopolysaccharide 
MAPK Mitogen activated protein kinase 
NO Nitric oxide 
p38 MAPK p38 mitogen activated protein kinase 
TNF-α Tumour necrosis factor alpha 
TfR Transferrin receptor 
VAMP Vesicle associated membrane protein 
v/v Volume to volume 
w/v Weight to volume
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1. Literature Review 
1.1. Natural products as alternative therapies 
Traditional medicine systems, which have existed for thousands of years, have 
amassed a huge amount of data in utilising natural products as therapies for various 
diseases. These age-old remedies offer a cheap and easily available alternative 
approach as a multi-target therapy for diseases such as cancer and inflammatory 
diseases which involve many different pathways as opposed to conventional therapies 
which focus on a single target (Gupta et al., 2010). In recent times, a larger amount of 
research has focused on the effect of natural product derived compounds in combating 
cancer, metabolic disorders, neurodegenerative diseases, inflammation and 
cardiovascular diseases (Houston, 2010; Kannappan et al., 2011). However, not much 
is known about the mechanisms through which these compounds affect cells. Hence 
we focus here on elucidating the effect and mechanism of andrographolide (ADO), an 
active component of the medicinal plant Andrographis paniculata, on receptor 
trafficking.  
 
1.2. Andrographis paniculata 
Andrographis paniculata (A. paniculata), commonly known as the “King of Bitters”, 
due to its extremely bitter taste, is a plant belonging to the family of Acanthaceae. In 
Mandarin, it is known as穿心莲 (Chuan Xin Lian). The plant grows in shaded areas, 
and is found in several Asian countries such as Malaysia, Indonesia, India, Thailand 
and Singapore. It is commonly used in Indian and Chinese complementary medicine 
treatments as an anti-inflammatory agent, and is also one of the active components in 





the Swedish drug, Kan Jang, sold by the Swedish Herbal Institute for the treatment of 
upper respiratory tract infections. Traditionally, it has been used for the treatment of 
snake bites. Various studies show that it can offer some protection against venom 
from cobra (Naja sp.) (Kumarapppan et al., 2011; Premendran et al., 2011), 
rattlesnake (Crotalus adamanteus) (Samy et al., 2008), as well as the deadly red 
scorpion (Mesobuthus tumulus) (Brahmane et al., 2011). A. paniculata extracts also 
prevented scorpion venom (Heterometrus laoticus) induced lysis of fibroblasts 
(Uawonggul et al., 2006). A. paniculata contains several active components of which 
a few have been more extensively studied – ADO, neoandrographolide, 
deoxyandrographolide, 14-deoxy-11,12-didehydroandrographide and 
isoandrographolide (Chao & Lin, 2010). Their chemical structures can be seen in 
figure 1.1. 
 
There are various methods of extracting active compounds from A. paniculata. 
Extraction of active compounds can be done using methanol, ethanol, ethyl acetate, 
hexane and water, and an excellent review of the various methods of extractions has 
been covered by Chao et. al. (Chao & Lin, 2010).  
 








Of all the active compounds found in A. paniculata, andrographolide (ADO) has been 
the most extensively studied, and has been shown to be a highly versatile compound 
(Figure 1.2). ADO is the main component that contributes to the bitter taste of A. 
paniculata as it acts as an agonist for the bitter taste receptor hTAS2R50 (Behrens et 
al., 2009). Much work has been carried out on the varying effects of ADO, and thus 
far, it is known that ADO has hepatoprotective effects against toxic substances like 
carbon tetrachloride, paracetamol, glucosamine and ethanol (Ghosh et al., 2011). It 
Figure 1.1 Chemical structures of various active compounds extracted from 
Andrographis paniculata. (Chao & Lin, 2010) 





has also been found to be effective in the killing of cancer cells, and as an anti-oxidant 
(Chao & Lin, 2010). A summary of the various effects of ADO is shown in figure 1.2. 
 
The majority of this literature review focuses on the compound ADO as it is the main 
active component of Andrographis paniculata, and it is much easier to investigate the 
effects induced by a purified compound as compared to plant extracts that consist of a 
mixture of various compounds. However, the effect of ADO may be limited in some 
contexts, hence various groups have synthesised different derivatives of ADO through 
varying the side chains in a bid to increase its efficacy (Jada et al., 2006; Wang et al., 
2010b; Aromdee et al., 2011; Aromdee, 2012). The literature review focuses on ADO 
effect on the immune system and on its anti-cancer effect, as those are the main areas 
of our investigation. 
   





  Figure 1.2 Summary of the wide variety of effects of andrographolide on various human 
disease conditions. 





1.4. Pharmacokinetics of andrographolide and andrographolide delivery 
systems 
 
The bioavailability of any drug is particularly important as it refers to the amount of 
drug that is made available to the system. The pharmacokinetics of ADO has been 
extensively studied in animal models and humans, and a variety of methods utilizing 
high performance liquid chromatography (HPLC) in combination with ultraviolet 
detection have been developed to quantitate the amount of available ADO in the 
plasma as summarised in table 8.1. These studies have found that the amount of free 
ADO within the plasma is rather low as a large proportion of ADO binds to plasma 
proteins, leading to reduced availability of free ADO in the blood (Panossian et al., 
2000). Another factor contributing to the low bioavailability of ADO is the 
metabolism of ADO as well as the efflux of ADO by P-glycoprotein, an important 
ATP efflux transporter in the intestine. Ye et al. found that incubating ADO with 
saline perfused through rat duodenum and jejunum led to the significant degradation 
of ADO, due to the rapid metabolism of ADO to form 14-deoxy-12-sulfo-ADO, 
which was detected in high amounts in the liver, kidney and blood 2 h after oral 
administration (Ye et al., 2011), and also as a metabolite in the urine of rats (He et al., 
2003). Absorption of ADO across the ileum and colon sections was also poor due to 
efflux of the drug by P-glycoprotein, which was inhibited upon the addition of P-
glycoprotein inhibitors.  
 
Hence, various groups have attempted to increase the bioavailability of ADO through 
different methods. One group tried to increase the poor solubility of ADO by spray 
drying the lipophilic ADO together with the water-soluble complex 
polyvinylpyrrolidone (PVP K-30). In comparison to isolated ADO as well as physical 





mixtures with PVP K-30, the solid dispersions (SD) of ADO-PVP K-30 only needed 
20 minutes, as compared to more than 120 minutes (isolated ADO and physical 
mixtures with PVP K-30), to release 75% of the drug. The SD of ADO-PVP K-30 
was also more efficacious therapeutically and it took only 30 minutes to reduce 
carrageenan induced paw oedema in rats by 50%, as compared to isolated ADO which 
took 3 h (Bothiraja et al., 2009). Maiti et al. utilised the phospholipid 1,2-distearoyl-
sn-glycero-3-phosphocholine to form a complex with ADO which they termed a 
herbasome (Maiti et al., 2010). An equivalent dose of ADO in the herbasome was 
able to generate a higher maximum plasma concentration of 9.64 µg/ml as compared 
to 6.79 µg/ml generated by ADO. The herbasome also increased the elimination half-
life of the drug by about 3 times, hence improving the bioavailability and 
hepatoprotective effect of ADO. Other groups attempted to package ADO in 
liposomes using phosphatidylethanolamine (PE), cholesterol, dicetyl phosphate (DCP) 
(Sinha et al., 2000; Suo et al., 2007); nanoparticles made of poly(DL-lactide-co-
glycolic acid) (PLGA) (Roy et al., 2010), or a pH sensitive patented material 
Eudragit® EPO as a matrix and Pluronic® F-68 as a surfactant (Chellampillai & 
Pawar, 2011) to facilitate drug release in the acidic environment of the gastrointestinal 
tract. Thus far, the method which maximises the amount of bioavailable ADO in 
pharmacokinetic studies after factoring in the difference in the dosage levels is the 
herbasome method which gives an area under the plasma concentration curve   









1.5. Side effects of andrographolide 
A main concern of any drug being utilised is the side effects that are associated with it. 
Andrographis paniculata extract has no known acute toxicity at a dose of 17 g/kg, nor 
subchronic toxicity (Burgos et al., 1997). A study conducted on a standardised extract 
of Andrographis paniculata, known as KalmCold™, which contains a variety of 
pharmacological compounds which include ADO, demonstrated that it has no 
genotoxic effects through three tests: the Ames test for dosages up to 5000 µg/ml, the 
in vitro chromosome aberration test and the in vitro micronucleus test for 
concentrations up to 80 µg/ml without metabolic activation and up to 345 µg/ml with 
metabolic activation. KalmCold™ also showed no acute oral toxicity in female rats at 
5000 mg/kg after an observation period of 14 days (Chandrasekaran et al., 2009). 
However, in a clinical trial consisting of HIV positive and healthy individuals 
utilising doses of ADO at 5mg/kg for 3 weeks followed by 10mg/kg for 3 weeks, 
adverse effects such as headache, fatigue, rash, itching of the skin were observed.. 
This led to the trial being stopped (Calabrese et al., 2000). Severe adverse effects 
were not noted at other clinical trials involving human volunteers.  
 
1.6. Andrographolide and Immune Suppression 
One of the most extensively characterised effects of ADO is its ability to suppress the 
immune system (Lim et al., 2011). It accomplishes this via the following mechanisms: 
inhibition of the NF-κB pathway (Xia et al., 2004; Bao et al., 2009), and inhibiting 
nuclear translocation of NFAT, which is an important transcription factor for genes 
mediating the differentiation of T cells, and is critical in the production of cytokines 
such as IL-2, IL-4, IL-6, IL-10, IL-13, IL-17, IL-21, IL-22, IFN-γ in Th1, Th2 and 
Th17 T cells. ADO also inhibits monocyte adhesion and migration. The anti-





inflammatory mechanism of ADO is likely to contribute to its ability to reduce 
symptoms in diseases where inflammation plays a role in disease progression: 
autoimmune diseases; cardiovascular diseases where vascular inflammation is 
involved like atherosclerosis; cancer and insulin resistance in diabetes (Chao & Lin, 
2010; Lim et al., 2011). The anti-inflammatory effects of ADO in vitro, in vivo and in 
clinical trials have been summarised in tables 8.2 to 8.4 respectively. 
 
1.6.1. ADO effect in vitro 
In vitro, ADO is known to inhibit the upregulation of pro-inflammatory molecules. 
For instance, ADO inhibited the upregulation of inducible nitric oxide synthase (iNOS) 
in RAW 264.7 macrophages activated with lipopolysaccharide (LPS) (Chiou et al., 
1998) through inhibiting synthesis of iNOS, as well as increasing its degradation 
(Chiou et al., 2000). Nitric oxide (NO), prostaglandin E2 (PGE2), IL-1β, IL-6 
production in LPS stimulated macrophages, as well as thromboxane B2 (TXB2) 
production in differentiated HL-60 leukaemia cells were also dose dependently 
inhibited (Chandrasekaran et al., 2011). TNF-α and IL-12 production was also 
reduced in ADO treated mouse peritoneal macrophages, and reduction of TNF-α 
levels is most likely due to suppression of the extracellular regulated kinase (ERK) 
pathway (Qin et al., 2006). IL-8 and TNF-α secretion were significantly decreased at 
a non-cytotoxic dose of ADO in human keratinocytes induced with dead 
Propionibacterium acne, the bacteria that cause acne, an inflammatory condition of 
the skin (Fu et al., 2011).  
 





Monocyte recruitment and adhesion were also reduced by ADO due to the 
downregulation of adhesion molecules. N-formyl-methionyl-leucyl-phenylalanine 
(fMLP) induced human peripheral neutrophils demonstrated a reduced level of 
adhesion and transmigration due to downregulation of surface levels of macrophage 
antigen-1 (Mac-1) upon ADO treatment. Mac-1 surface expression is controlled by 
the levels of reactive oxygen species (ROS) in neutrophils, which was lowered with 
ADO  (Shen et al., 2002). Chemotactic migration of macrophages induced by 
complement 5a (C5a) was repressed by ADO treatment as it was capable of 
suppressing the downstream signalling cascades of mitogen associated protein 
extracellular kinase 1/2 (MEK1/2) and phosphoinositide 3 kinase (PI3K) activation. 
Migration induced by macrophage inflammatory protein 1-α was also inhibited upon 
ADO treatment (Tsai et al., 2004). ADO could also reduce adhesion of HL-60 
promyeloid leukaemia cells to EA.hy926 and human umbilical vein endothelial cells 
by inhibiting the upregulation of intercellular adhesion molecule 1 (ICAM-1) upon 
TNF-α stimulation (Yu et al., 2010; Chen et al., 2011).  
 
In T lymphocytes, the translocation of the transcription factor, nuclear factor of 
activated T cells (NFAT1), into the nucleus upon stimulation by phorbol myristate 
acetate (PMA) and ionomycin was inhibited, hence reducing the production of 
cytokines such as IL-2 (Carretta et al., 2009). This inhibition was linked to ADO’s 
upregulation of c-Jun-N-terminal kinase (JNK) phosphorylation, which is known to 
phosphorylate NFAT1. JNK phosphorylation of the calcineurin targeting domain of 
NFATcI (transcription factor) prevents calcineurin from dephosphorylating NFAT, 
and hence inhibits NFATI nucleus translocation. (Chow et al., 2000).  






One of the key findings, which reveals the anti-inflammatory effect of ADO, is the 
discovery that ADO inhibits NF-κB binding to DNA by modifying the cysteine 
residue 62 on the p50 subunit. This critical discovery of ADO inhibition of the NF-κB 
pathway was carried out by two groups at about the same time: Hidalgo et al. 
discovered that NF-κB binding to DNA in platelet-activating factor (PAF) and fMLP 
induced HL-60 derived neutrophils was inhibited (Hidalgo et al., 2005), and Xia et al. 
demonstrated similarly that NF-κB binding was affected in TNF-α treated 293T cells. 
They went further to identify that the cysteine residue 62 is modified by ADO through 
mutation studies. As NF-κB is inhibited, E-selectin expression on activated 
endothelial cells was decreased hence leading to decreased leukocyte adhesion (Xia et 
al., 2004).  
 
NF-κB inhibition also led to the inhibition of dendritic cell (DC) maturation after 
induction by LPS. Thus, antigen presentation by DCs to T cells, as well as the surface 
expression of molecules important for T cell activation like MHC class II, CD40 and 
CD86 was also diminished upon ADO treatment, leading to the inhibition of T cell 
activation, as well as a reduction in antibody production against the antigen of interest. 
Interestingly, phagocytosis remained unaffected upon ADO treatment (Iruretagoyena 
et al., 2005; Iruretagoyena et al., 2006).  
 
Cyclooxygenase-1 (COX-1), is constitutively active, while COX-2 is an inducible 
target gene for NF-κB, and is responsible for the production of pro-inflammatory 
prostaglandins and its product thromboxanes, as well as leukotrienes. ADO was 





shown to inhibit both COX-1 and COX-2 activities in human platelet cell suspensions, 
and it also decreased the total level of pro-inflammatory cytokines in human whole 
blood such as TNF-α, IL-6, IL-1β and anti-inflammatory cytokine IL-10 due to 
downregulation of mRNA expression (Parichatikanond et al., 2010) 
 
ADO also inhibited LPS induced neurotoxicity and activation in dopaminergic 
neuronal cultures. Hence, LPS induced superoxide, TNF-α, nitric oxide and PGE2 
production and intracellular reactive oxygen species (ROS) levels were also reduced. 
LPS induced mRNA expression of COX-2 and TNF-α was similarly decreased upon 
ADO treatment, and protein stability of COX-2 dropped (Wang et al., 2004). This 
finding was further substantiated in a rat model of permanent cerebral ischaemia, 
where rats were administered ADO after ischaemia was induced. A reduction in 
infarct volume and decrease in activated OX-42 microglia, as well as a drop in IL-1β, 
TNF-α and PGE2 production in the ischaemic hemisphere in ADO treated rats was 
observed. The amount of NF-κB translocated into the nucleus from the cytosol was 
also decreased upon ADO treatment, accounting for the drop in pro-inflammatory 
cytokines (Chan et al., 2010). 
 
1.6.2. ADO effect in animal disease models 
In vivo, ADO has been proven to be efficacious in a variety of autoimmune mouse 
models, including asthma, peritonitis, septic shock, experimental autoimmune 
encephalomyelitis (EAE) and hemophilia.  
 





ADO has been demonstrated to inhibit the effects of ovalbumin (OVA) induced 
asthma in sensitized mice. In ADO treated asthmatic mice, infiltrating leukocyte cell 
count dropped compared to control mice; levels of OVA- specific IgE and pro-
inflammatory cytokines such as IL-4, IL-5, IL-13 were also decreased in 
bronchoalveolar lavage fluid. Interestingly, ADO was found to prevent activation of 
the NF-κB pathway further upstream by inhibiting phosphorylation of inhibitory κB – 
kinase β (IKKβ) upon induction with tumour necrosis factor-α (TNF-α) (Bao et al., 
2009). LPS induced E-selectin and vascular cell adhesion molecule 1 (VCAM-1) 
upregulation on endothelial cells in the blood vessels from the lungs of asthmatic 
mice was also downregulated upon ADO treatment (Xia et al., 2004).  
 
In mouse models of peritonitis induced by TNF-α, IL-1β or LPS, the infiltrating 
neutrophils were decreased in number upon ADO treatment, whereas in the mouse 
model of septic shock induced by LPS, the rate of mouse survival was improved upon 
treatment (Xia et al., 2004). The severity of EAE, the mouse model of the human 
disease multiple sclerosis, was also decreased upon ADO treatment, due to inhibition 
of DC maturation, leading to reduction of antimyelin T cell and antibody response in 
ADO treated mice. In addition, numbers of Fox3p regulatory T cells were increased in 
ADO treated mice (Iruretagoyena et al., 2005; Iruretagoyena et al., 2006). Not 
surprisingly, in a separate test for the humoral response upon vaccination, serum 
antibody titres of mice injected with the yeast derived human hepatitis B surface 
antigen (HBsAg) and treated with ADO were decreased in comparison to the control 
(Wang et al., 2010a). 
 





In the mouse models for nociception, the acetic acid induced writhing test and the hot-
plate tests were used for mice pretreated with ADO, and ADO was shown to reduce 
the levels of pain induced through a non-opioid mechanism (Suebsasana et al., 2009). 
Intraperitoneal injection of ADO was capable of reducing the swelling of the paw 
(Sheeja et al., 2006; Suebsasana et al., 2009; Sulaiman et al., 2010) in the carageenan 
induced paw oedema mouse model, which is dependent on COX-2 induction of 
prostaglandin E2 production (Guay et al., 2004). ADO suppression of edema is not 
surprising as it is capable of inhibiting NF-κB and COX-2 activity. A separate study 
by Suebsasana et al. on mice for baker’s yeast induced fever, the writhing test and hot 
plate tests showed no effect of ADO. However, this is likely to be due to the 
differences in the dosage of ADO used, as Suebsasana et al. used a much lower dose 
of 4 mg/kg as compared to Sulaiman et al., who used dosages up to 50 mg/kg 
(Suebsasana et al., 2009; Sulaiman et al., 2010).  
 
In a haemophilic mouse model, ADO led to the increased secretion of 
immunosuppressive cytokines IL-10 and TGF-β in an immature dendritic cell-T cell 
co-culture, as well as decrease in factor VIII (FVIII) inhibitors, which are responsible 
for sequestering the FVIII protein infused as therapy for Haemophilia A (Qadura et al., 
2008). 
 
Not surprisingly, ADO was similarly effective in animal models of vascular 
inflammation, as NF-κB is the main signal integrator which responds to cytokines and 
vasoactive peptides, and its activation results in monocyte adhesion and chemotaxis 
into the vascular tissue, and finally monocyte activation. Monocytes then release 





reactive oxygen species and activate metalloproteinases which cause the remodelling 
of the extracellular matrix (Brasier, 2010). In a mouse model of arterial injury, ADO 
treatment had the same effect on inhibiting neointima hyperplasia as NF-κB p50 
knock-out mice. As NF-κB controls transcription of E-selectin, vascular cell adhesion 
molecule-1 (VCAM-1) and tissue factor (TF), it was not surprising that ADO treated 
mice had decreased E-selectin, VCAM-1 and TF protein and mRNA expression levels. 
The decreased E-selectin and VCAM-1 levels on endothelial cells led to reduced 
leukocyte deposition (Wang et al., 2007). A separate study on vein graft in rats 
similarly demonstrated a reduction in intima hyperplasia for ADO treated rats. 
Similarly, E-selectin, p65 subunit of NF-κB and matrix metalloproteinase-9 (MMP-9) 
expression was also downregulated in ADO rats (Zhi-Tao et al., 2011). In primary 
cultures of rat vascular smooth muscle cells (VSMCs) induced with both LPS and 
IFN-γ, production of NO, an inflammatory mediator from VSMCs was decreased 
upon ADO treatment. Both iNOS protein and mRNA levels were also decreased upon 
addition of ADO; production of matrix metalloproteinase-9 (MMP-9), a hallmark of 
vascular inflammatory disease, also dropped after treatment. This was due to the 
reduction in NF-κB transcription activity, as ADO led to reduced nuclear 
translocation of NF-κB (Hsieh et al., 2010). 
 
Thrombosis is a condition where activation of coagulation factors leads to platelet 
activation and aggregation, finally forming a blood clot, leading to ischaemic 
conditions. TF plays a pivotal role in initiating thrombosis as it triggers the 
coagulation cascade, causing the formation of a fibrin clot which obstructs blood flow. 
In a mouse model of deep vein thrombosis, both p50 knockout mice and ADO treated 





mice showed a reduction in the amount of TF produced, as well as a drop in the levels 
of fibrin deposited. Proliferation of venous endothelial cells, upregulation of E-
selectin and VCAM-1 levels and leukocyte infiltration were also reduced in both 
types of mice (Li et al., 2009).  ADO treatment was able to inhibit platelet 
aggregation in both platelet aggregation factor (PAF) induced human blood platelets 
(Amroyan et al., 1999; Thisoda et al., 2006) and thrombin induced rat platelets 
(Thisoda et al., 2006), which could prevent clot formation, through the inhibition of 
ERK2. Sodium induced microthrombus formation in mice was also delayed upon 
treatment with ADO, with a longer time period needed for vessel occlusion and 
lowered mortality rate. This is due to inhibition of platelet aggregation, which arose 
from inhibition of the phosphatidylinositol-3 kinase (PI3K)-Akt-p38 MAPK and 
phospholipase C γ-2 (PLC γ-2)-diacylglycerol (DAG)-protein kinase C (PKC) 
pathways and  through activation of the endothelial nitric oxide synthase (eNOS)-
nitric oxide (NO)-cyclic GMP pathway, which led to the decreased release of calcium 
ions, which are important for platelet activation (Lu et al., 2011).  
 
1.6.3. ADO in clinical trials  
In humans, ADO typically makes up one of the components in a herbal concoction. 
Thus far, the available commercial products which contain ADO are Immunoguard®, 
Kan Jang SHA-10 as well as Paractin® tablets, made up of 30% ADO. Various 
reviews conducting a meta-analysis of the clinical trials focusing on upper respiratory 
tract infection found that either A. paniculata extract or its combination with 
Eleutherococcus senticocus was able to significantly contribute to an improvement of 
symptoms. The drug is also generally safe as there were low incidences of adverse 





reactions, and these adverse reactions were mild and infrequent (Coon & Ernst, 2004; 
Poolsup et al., 2004; Kligler et al., 2006).   
 
Immunoguard®, a mixture of Andrographis paniculata, Eleutherococcus senticosus, 
Schizandra chinensis, Glycyrrhiza glabra, has been tested in patients with a genetic 
inflammatory disease – familial Mediterranean fever (FMF) in a double blind placebo 
controlled trial. Such patients typically experience attacks lasting two to four days in 
the form of fever, inflammation in the lungs, abdominal cavity, joints and peritoneal 
cavity. Immunoguard® was found to reduce the number, duration and severity of 
attacks (Amaryan et al., 2003). Interestingly, it worked by increasing the amount of 
NO to normal levels, as well as by decreasing elevated levels of the pro-inflammatory 
cytokine IL-6 (Panossian et al., 2003).  
 
Kan Jang is a combination of Andrographis paniculata and Eleutherococcus 
senticosus, and administration of Kan Jang to patients with an upper respiratory tract 
infection and sinusitis in a double blind, placebo controlled study resulted in a 
reduction of sore throat, dryness in throat, nasal symptoms, headache and general 
malaise (Melchior et al., 2000; Gabrielian et al., 2002; Kulichenko et al., 2003). 
When tested in children using Immunal (a concoction containing 80% Echinacea 
purpurea juice and 20% ethanol) as the control, patients who consumed Kan Jang also 
recovered more rapidly overall, and had decreased nasal secretion and nasal 
congestion (Spasov et al., 2004).    
 





Paractin, a formulation consisting of 30 mg ADOs, was fed to rheumatoid arthritis 
(RA) patients 3 times a day for 14 week in a randomized, double blind, placebo 
controlled study (Burgos et al., 2009). ADO treatment reduced the number and grade 
of swollen and tender joints, together with a reduction in the levels of rheumatoid 
factor (RF), IgM and IgA. In vitro studies showed that the ADO effect on relieving 
RA symptoms could also be due to its ability to reduce proliferation, induce cell cycle 
arrest and apoptosis in human primary rheumatoid arthritis fibroblast like 
synoviocytes (RAFLSs) extracted from rheumatoid arthritis patients. RAFLSs are 
known to contribute to inflammation and cartilage destruction by secreting pro-
inflammatory cytokines and metalloproteases (Bartok & Firestein, 2010). Upon ADO 
treatment in RAFLs, expression of anti-apoptotic protein Bcl-2 was decreased, 
whereas pro-apoptotic Bax was upregulated; cytochrome c was also released leading 
to the cleavage of pro-apoptotic caspase-3. (Yan et al., 2011) 
 





1.7. Andrographolide and Immunostimulation  
 
Although ADO is known to be anti-inflammatory, some studies have actually 
demonstrated that it can induce the immune system (table 8.5) through increasing the 
proliferation of lymphocytes. Human immunodeficiency virus (HIV) positive patients 
who took 10 mg/kg of ADO had a statistically significant 23% increase in the number 
of CD4
+
 lymphocytes which corresponded to no change in the HIV viral mRNA 
levels.(Calabrese et al., 2000). Proliferation of phytohemagglutinin (PHA) induced 
human peripheral blood lymphocytes (HPBL) was significantly increased by about 5% 
when ADO was added, but decreased by 16.4% in the presence of Kan Jang. ADO and 
Kan Jang also increased the amount of pro-inflammatory cytokine IFN-γ secreted in the 
absence of PHA, and TNF-α in the presence of PHA. Neopterin, which is an indication 
of lymphocyte activation, and β-2-microglobulin (β2MG), which is a component of the 
MHC class I molecule which is responsible for antigen presentation, were increased 
upon treatment in the absence of PHA; β2MG levels were also increased in the 
presence of PHA after treatment (Panossian et al., 2002). Non-PHA induced HPBL 
were also induced to proliferate upon ADO treatment, with an increase in IL-2 
secretion (Kumar et al., 2004).  
 
Interestingly, lymphocyte proliferation was insignificant in mice immunized with sheep 
red blood cells (SRBC), but SRBC specific antibody titres, which is representative of 
the humoral response, as well as hemolytic plaque forming cells and delayed type 
hypersensitivity response, which are measures of cell mediated immunity, were 
increased upon treatment with ADO or ethanol extract of A. paniculata (APE) (Puri et 
al., 1993). Mice gavaged with either ADO or APE and then immunized with 
inactivated Salmonella typhimurium also showed enhancements in humoral and cell-





mediated immunity as evidenced by huge increases in serum IgG specific for 
Salmonella, as well as the amount of IFN-γ secreted by splenocytes (Xu et al., 2007). 
Synthesis and secretion of the macrophage migration inhibitory factor (MIF), which is 
an important pro-inflammatory cytokine that has several functions including 
upregulating Toll like receptor 4 and prostaglandin E2 expression (Calandra & Roger, 
2003), is also increased upon ADO treatment, although other NF-κB inhibitors such as 
gliotoxin and oridonin have a more significant effect. This effect in MIF is probably 
due to the increase in superoxide anion, and is likely to be mediated via the 
phosphatidylinositol-3-kinase/Akt/JNK pathway (Cho et al., 2009). 
 
1.8. Anti-cancer effects of andrographolide  
The six hallmarks of cancer as defined by Douglas Hanahan and Robert Weinberg are: 
the ability to sustain proliferative signalling; evading growth suppressors; activating 
invasion and metastasis; enabling replicative immortality; inducing angiogenesis and 
resisting cell death (Hanahan & Weinberg, 2011). ADO is able to counter these 
characteristics through inhibiting proliferation; inducing cell cycle arrest and cell 
death by apoptosis; decreasing metastasis and angiogenesis as well as triggering the 
anti-tumourigenic cytotoxic immune response (table 8.6). Some of these effects are 
focused on in the review below.  
1.8.1. Inhibition of cellular proliferation and induction of apoptosis 
ADO was capable of inhibiting proliferation of various cancer cells, including cell 
lines from the colon, breast, central nervous system (CNS), lung, skin (melanoma), 
prostate, ovarian and renal systems (Kumar et al., 2004; Nanduri et al., 2004; Kim et 
al., 2005). Cell cycle progression is mediated by the differing levels of cyclin-





dependent kinases (Cdks) and cyclins. Progression into the S and M phases are critical 
for the proliferation of cells, and cell cycle arrest is one of the ways in which ADO 
stops the proliferation of cancer cells. ADO was found to induce cell cycle arrest at 
the G0/G1 phase (Rajagopal et al., 2003; Satyanarayana et al., 2004; Cheung et al., 
2005) as well as the G2/M phase (Li et al., 2007). 
 
Investigations on the levels of cyclins and cdks found that there was a corresponding 
upregulation of p27, a Cdk inhibitor (CKI) which inhibits activity of the cyclin-Cdk 
complex, as well as a decrease in Cdk 4 levels, which controls progression past late 
G1 (Satyanarayana et al., 2004). In Lovo cells, G1 arrest corresponded with a 
decrease in cyclin D/Cdk 4 and cyclin A/Cdk 2 complexes which are the G1-Cdk and 
S-Cdk complexes respectively and upregulation of CKIs p21 & p16 which suppress 
G1-Cdk activities. p53 phosphorylation upon ADO treatment was responsible for the 
transcription of p21, while the increase in Rb/E2F complex prevented E2F from 
transcribing proteins required for cell cycle progression (Shi et al., 2008).  
 
Induction of apoptosis was observed in cells treated with ADO, with characteristic 
morphological changes such as plasma membrane blebbing, vacuolisation, DNA 
condensation and fragmentation (Cheung et al., 2005; Kim et al., 2005; Li et al., 2007; 
Manikam & Stanslas, 2009). Flow cytometry studies also show treated cells to be 
Annexin V positive, which is a marker for early apoptosis, demonstrating 
translocation of phosphatidylserine from the inside leaflet to the outside (Gunn et al., 
2011). There are two possible pathways through which apoptosis could be induced: 
the extrinsic pathway which involves death receptor activation, leading to formation 
of the death receptor induced signalling complex (DISC) and cleavage of procaspase-





8, and downstream activation of caspase-3; and the intrinsic pathway, which involves 
cytochrome c release from the mitochondria which leads to formation of the 
apoptosome involving caspase-9 and downstream caspase-3 activation (Vermeulen et 
al., 2005). Pro-apoptotic proteins and anti-apoptotic proteins play important roles in 
both pathways, as illustrated by figure 1.3.  Cleavage of pro-apoptotic Bid by caspase-
8 leads to Bax conformational change, oligomerization and mitochondria 
translocation of Bax, resulting in cytochrome c release from the mitochondria and loss 
of mitochondria membrane potential.  
 
ADO induces apoptosis through the extrinsic pathway of caspase-8, (Kim et al., 2005; 
Zhou et al., 2006; Yang et al., 2009b; Yang et al., 2010), causing cleavage of pro-
apoptotic proteins such as Bid, upregulation of Bax (Cheung et al., 2005; Li et al., 
2007), Bax conformational change, and mitochondria translocation of Bax (Zhou et 
al., 2006; Yang et al., 2010), together with and decrease in anti-apoptotic Bcl-2 (Zhao 
et al., 2008). This led to a decrease in the mitochondria membrane potential, with a 
corresponding release of cytochrome c (Cheung et al., 2005; Yang et al., 2009b) 
causing downstream caspase-9 and caspase-3 activation (Zhao et al., 2008; Gunn et 
al., 2011). Expression of p53, an important transcription factor responsible for pro-
apoptotic genes such as Bax and the death receptor 4 (DR4), is also elevated (Li et al., 
2007; Sukardiman et al., 2007; Shi et al., 2008; Zhou et al., 2008) upon ADO 
treatment. p53 upregulation was due to its phosphorylation on threonine 81 by JNK 
activation (Zhou et al., 2008), leading to increased stabilization and decreased 
degradation.  
 





JNK activation was caused by a drop in cellular glutathione (GSH) in the presence of 
ADO and buthionine sulfoximine (BSO), an inhibitor of cellular GSH biosynthesis. 
ADO increases GSH synthesis due to increased expression of glutamate cysteine 
ligase (GCL), but GSH synthesis is halted in the presence of BSO. This resulted in 
activation of the upstream apoptosis signal regulating kinase 1 (ASK1) and its 
downstream kinases (Ji et al., 2011).  






Figure 1.3 Extrinsic and intrinsic pathways of apoptosis and roles of pro-
apoptotic and anti-apoptotic proteins. (Ola et al., 2011). Permission granted courtesy 
of Springer. 





1.8.2. Inhibition of tumour-promoting signalling 
Another anti-cancer mechanism through which ADO acts is inhibition of signalling 
pathways which are capable of causing tumour growth. IL-6 is an important cytokine 
which is an autocrine that promotes growth in human prostate cancer cells, and ADO 
suppression of IL-6 synthesis and expression led to the inhibition of downstream IL-6 
signalling targets – STAT3, ERK1/2 and Akt. This caused the induction of apoptosis, 
inhibiting tumour growth, and migration of cancer cells (Chun et al., 2010). Another 
important receptor involved in prostate cancer growth is the androgen receptor (AR), 
which is especially important for castration resistant prostate cancer survival. AR is 
upregulated in presence of dihydrotestosterone (DHT), and DHT is responsible for 
inducing prostate growth as well as progression of prostate cancer. In both the 
presence and absence of DHT, ADO could decrease AR synthesis and expression, as 
well as nuclear translocation of AR, inhibiting transcription of downstream genes 
such as the prostate-specific antigen (PSA); ADO also disrupted AR binding to heat 
shock protein 90, reducing the stability of AR. These effects on AR combined to 
induce apoptosis and reduce cell viability (Liu et al., 2011). 
 
ADO is capable of suppressing constitutive activation of signal transducers and 
activators of transcription-3 (STAT3), a transcription activator, as well as IL-6 
induced STAT3 activation. Upon activation, STAT3 is phosphorylated and 
translocates to the nucleus to initiate transcription of genes involved in cell cycle 
progression such as cyclin D1 and c-Myc (Quesnelle et al., 2007). ADO suppression 
of STAT3 is due to its inhibition of Janus activated kinase (JAK) 1 and 2 signalling, 
causing a decrease in STAT3 association with gp130, and decrease in nuclear 





translocation. This led to sensitization of various cancer cell lines that were previously 
resistant to doxorubicin (Zhou et al., 2010).  
 
Although activation of the immune system is important to protect the host from 
infection, chronic inflammation is known to lead to carcinogenesis, due to release of 
reactive oxygen species and nitric oxide, which can lead to cellular mutagenesis. 
During inflammation, NF-κB, a pro-survival signalling pathway, is activated. ADO is 
immunosuppressive and known to be able to inhibit the NF-κB signalling pathway in 
immune cells (Xia et al., 2004), and ADO treatment on Ras-transformed cancer cells 
and tumour growth inhibited the pro-survival signalling pathways Akt and NF-κB, 
sensitizing them to radiation (Hung et al., 2010). NF-κB inhibition by ADO was 
similarly replicated in an oral squamous carcinoma hamster model and Tb human 
tongue squamous cell carcinoma cells, resulting in cell cycle arrest, increase in 
apoptosis and decrease in cancer cell proliferation (Wang et al., 2011).  
 
1.8.3. Inhibition of migration  
One of the hallmarks of cancer progression is the loss of adhesion and acquisition of 
the ability to metastasize from the site of the primary tumour. Thus, one of the 
approaches to treat cancer is to target the metastatic capability of the tumour, and the 
anti-cancer candidate ADO is able to inhibit migration and invasion of lung (Lee et al., 
2010) and colorectal cancer cells (Shi et al., 2009; Chao et al., 2010a) by various 
mechanisms. 
 
Src is an oncogenic tyrosine kinase controlling various signalling pathways, and 
transformation of cells with the constitutively active mutant v-Src results in change in 





cellular morphology, loss of adhesion and increase in invasion ability. In ADO treated 
v-Src transformed cells, morphology transformation, decrease of the adhesion 
molecule E-cadherin and actin filament disorganization is inhibited. This is due to 
decreased v-Src protein expression due to increased ubiquitination, leading to a 
cellular decrease in tyrosine phosphorylation. Increased phosphorylation of ERK1/2 
mediates v-Src transformation of cells, and it is also inhibited upon ADO treatment. 
Hence, ADO can inhibit oncogenic transformation of cells (Liang et al., 2008). 
 
Cleavage of cell adhesion to the extracellular matrix by the matrix metalloproteases 
(MMP) is one of the steps for tumour cells to acquire mobility. One of the 
mechanisms by which ADO is anti-metastatic is its ability to inhibit the activity, 
synthesis and protein expression of MMP-7. One of the transcription factors 
responsible for synthesizing MMP-7 is the AP-1 complex, and AP-1 DNA binding is 
lowered upon ADO treatment. This is due to inhibition of the PI3K signalling 
pathway, which lowered c-Jun and c-Fos nuclear translocation, make up the AP-1 
complex (Shi et al., 2009; Lee et al., 2010). MMP-2 activity was also decreased 
without affecting its expression, and ERK signalling, which is responsible for 
promoting invasion, was inhibited (Chao et al., 2010a).   
 
In the initial process of metastasis, cancer cells leave the primary tumour site to enter 
circulation in the bloodstream, and they bind to endothelial cells in the vessel walls 





) in order for them to undergo extravasation. ADO is known to 
decrease gastric cancer cells adhesion to the TNF-α induced endothelium through 





downregulating E-selectin expression on endothelial cells and its binding partner Sle
x 
(Jiang et al., 2007).  
 
1.8.4. Induction of cytotoxic immune response 
Induction of the cytotoxic immune response is an important mechanism for control of 
cancer progression, since cytotoxic ADO and the ethanol extract of A. paniculata 
(APE) can induce an increase in natural killer (NK) cell activity, antibody-dependent 
cell-mediated cytotoxicity (ADCC) and antibody-dependent complement-mediated 
cell cytotoxicity (ACC) in Erhlich Ascites Carcinoma (EAC) tumour bearing mice. 
Mitogens such as concavanalin A, phytohaemagglutinin, and in some cases, poke 
weed mitogen or lipopolysaccharide, together with ADO and APE enhanced the 
proliferation of splenocyte, thymocyte and bone marrow derived cells. Cytokines such 
as IL-2, which controls T cell proliferation, and IFN-γ, which enhances MHC class I 
presentation of antigens and has anti- tumour activity, were also upregulated (Sheeja 
& Kuttan, 2007b). Similar results were seen for B16F10 metastatic melanoma tumour 
bearing mice (Sheeja & Kuttan, 2010), and EL4 thymoma cells (Sheeja & Kuttan, 
2007a). 
 
ADO can also be used in combination with other forms of anti-cancer therapy such as 
chemotherapy, radiotherapy and hyperthermia treatment to augment the immune 
system. Treatment using ADO in combination with these other therapies results in 
increased white blood cell count, decreased tumour volume, upregulation of pro-
inflammatory cytokine production (IL-2. GM-CSF, TNF-α), and decreased 
myeloperoxidase levels. Myeloperoxidase levels are associated with tumour 
development (Sheeja & Kuttan, 2008).   






In addition to the above effects, ADO also has other anti-neoplastic effects. One of the 
treatments to inhibit uncontrolled proliferation of promyelocytic leukaemia cells is to 
induce differentiation of these cells through activating the retinoic acid receptor 
pathway to form mature granulocytes. In addition to inducing apoptosis of these cells, 
ADO is capable of inducing differentiation in a retinoic acid receptor independent 
manner at the low dose of 4.5 µM (Manikam & Stanslas, 2009), causing them to have 
a restricted reproductive capability. Short treatments with ADO can also reduce levels 
of hypoxia inducible factor-1 α (HIF-1α) in non small cell lung cancer (NSCLC) 
through inhibiting the transforming growth factor – β signalling pathway, leading to 
increased proteolytic degradation of HIF-1 α. This inhibits vascular endothelial 
growth factor (VEGF) signalling, hence inhibiting cancer growth (Lin et al., 2011)  
 
In summary, ADO is capable of acting as cytotoxic agent either on its own, or in 
combination with different chemotherapy agents such as 5-fluorouracil (FU) and 
tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL); it can induce 
cytotoxicity in cancers which may be resistant to classical therapies; or apoptosis in 
cancer cells. It is also capable of inhibiting pro-tumourigenic signalling pathways, 
angiogenesis as well as migration. Cancer cell sensitivity to chemotherapy could also 
be restored in multidrug resistant cancer cell line by ADO treatment, possibility due to 
lower expression of the efflux glycoprotein P-170 (Han et al., 2005). 
 











Materials and Methods  





2. Materials and Methods 
2.1. Maintenance of cell lines 
2.1.1. Media and growth conditions 
 
A-431 human skin epithelial carcinoma cells (CRL-1555), Hela (CCL-2) and N9 
microglia were obtained from ATCC, and cultured in Dulbecco’s Modified Essential 
Medium (DMEM) (Gibco, Singapore). 
 
DMEM was supplemented with fetal bovine serum (FBS) (Gibco, Singapore), 2 mM 
L-glutamine (Gibco, Singapore), 0.1 mM non-essential amino acids (Gibco, 
Singapore), 5 mM HEPES buffer (pH 7.2-7.5) (Gibco, Singapore) and 1X antibiotic-
antimycotic (Gibco, Singapore). All cells were grown at 10% FBS (v/v) with DMEM 
with the exception of A-431, which was grown with 5% FBS in DMEM. Cells that 
were serum-starved were grown in DMEM with all the above supplements except 
FBS. Cells were routinely grown at 37 ºC with 5 % CO2. 
 
Cells were dislodged from the culture flasks by incubation with 0.25 % trypsin-EDTA 
in phosphate buffered saline (PBS) (Gibco, Singapore) for approximately 10 min, and 
trypsin was inactivated with the addition of complete media. Cells were then pelleted 
at 1500 rpm at room temperature for 5 min, resuspended in fresh media and seeded 
accordingly. 
2.1.2. Cryopreservation of cell lines 
A confluent flask of cells was trypsinised and pelleted. The cell pellet was then 
resuspended in a solution with 90 % FBS and 10 % DMSO as the cryoprotectant and 
frozen at –80 °C, and in liquid nitrogen for long term storage.  






The primary antibodies used are: anti-EGFR (Clone F4, Sigma, Singapore); anti-
phosphorylated EGFR (BD Bioscience, San Jose, California, USA), anti-TfR (OKT9, 
monoclonal hybridoma), anti-CD204 (AbD Serotec, Oxford, UK), anti- early 
endosomal antigen-1 (Santa Cruz Biotechnology, California, USA), anti-β-actin 
(Sigma, Singapore), anti-vesicle associated membrane protein-3 (VAMP-3), VAMP-8 
(Synaptic Systems, Germany), anti-lysosomal associated membrane protein-1 
(LAMP-1) (eBiosciences, San Diego, USA). Secondary fluorescence-conjugated 
antibodies were obtained from Jackson Laboratory, and secondary horse radish 
peroxidase conjugated antibodies were obtained from Thermo Scientific. 
Table 2.1 Catalogue of primary antibodies used 
Antibodies against Clone (for 
mAb) 
Company Reference 
Epidermal growth factor 
receptor (EGFR) 
Clone F4 Sigma - 
Phosphorylated EGFR 74 BD Bioscience - 
Phosphorylated EGFR 
(serine 1046/ 1047) 
N.A. Cell Signaling - 
Epidermal growth factor 
receptor (EGFR), 
extracellular domain. 
Clone LA1 Millipore - 
Epidermal growth factor 
receptor (EGFR), 
extracellular domain. 
Clone 29.1 Sigma  




CD204 Clone 2F8 AbD Serotec - 
early endosomal antigen-
1 
N.A. Santa Cruz 
Biotechnology 
- 








N.A. Synaptic Systems - 














N.A. Thermo Scientific - 
CD36 CRF D-2712 BD Bioscience - 
MARCO ED31 AbD Serotec - 
phosphorylated ERK1/2 N.A. Cell Signalling - 
ERK1/2 N.A. Cell Signalling - 
Phosphorylated JNK N.A. Cell Signalling - 
JNK N.A. Cell Signalling - 
Phosphorylated p38 
MAPK 
N.A. Cell Signalling - 
p38 MAPK N.A. Cell Signalling - 
 
2.3. Other Reagents 
ADO of purity ≥ 95% was purchased directly from Calbiochem, resuspended in 
DMSO to give a stock solution of 50 mM and stored at –20 °C. Alexa-fluor 488 
labelled transferrin and alexa-fluor 555 EGF were purchased from Molecular Probes, 
resuspended in sterile water to give a final concentration of 2 mg/ml (transferrin) or 
200 μg/ml (EGF). Human recombinant EGF was purchased from Roche Applied 
Science, resuspended in sterile water to give a stock solution of 0.5 mg/ml. Holo-
transferrin was purchased from Sigma and resuspended in sterile water to give a stock 
solution of 2 mg/ml. Carboxylate modified fluorescent green 1 µm latex beads for 
phagocytosis assays were purchased from Sigma-Aldrich. 
2.4. Cellular Analysis 
2.4.1. Cell Viability Assay 
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma) as previously described (Li et al., 2007; 
Pannecouque et al., 2008). Briefly, cells were seeded into a 96 well microplate and 
routinely cultured. Cells were then exposed to ADO (0-160 μM) for 24 h. The amount 





of DMSO (1% v/v) in each well was standardised across all samples. 20 μl of 
tetrazolium dye solution (5 mg/ml in phosphate buffered saline, PBS) was added to 
each well and incubated for 1 h with shaking in the dark. Cells were then lysed 
overnight in the presence of lysis buffer at 37 ºC to dissolve the formazan crystals. 
The absorbance was then read using a microplate reader (Tecan Gemini Infinite 200) 
at 540 nm, and with reference filter at 690 nm to deduct for absorbance due to cell 
debris.  
2.4.2. Indirect Immunofluorescence 
2.4.2.1. Steady State Studies 
Immunofluorescence microscopy was performed as described previously (Wong et al., 
1998; Wong et al., 1999). Briefly, cells grown on coverslips were treated for 4 h with 
DMSO (0.2% v/v) or ADO and fixed in 4% (w/v) paraformaldehyde on ice. After 
fixing, the cells were then permeabilized with 0.1% (w/v) saponin (Sigma) in PBS, 
and stained with the corresponding primary antibodies and secondary fluorescence-
conjugated antibodies (Jackson Immunoresearch). The coverslips were mounted using 
fluorescence mounting medium (Vector Laboratories). Conventional images were 
taken with the fluorescent microscope (Olympus BX60). 
 
2.4.2.2. Endocytosis Studies 
Cells were serum starved when labelled epidermal growth factor (EGF) was used in 
the experiment. The cells were pretreated with DMSO (0.2% v/v) or ADO for 30 min, 
then incubated with mouse antibody EGFR (Clone 29.1, Sigma, Singapore), or 1.6 
μg/ml Alexa Fluor 555- labelled epidermal growth factor (EGF) (Invitrogen, 
Singapore) or mouse anti transferrin receptor OKT9 for 1 h on ice, to allow the 





antibody or ligand to bind to cell surface receptors. Cells were then replaced into 
media containing DMSO (0.2% v/v) or ADO, washed and fixed at the appropriate 
time points, then stained and mounted in the manner stated above. Confocal 
microscopy was carried out using the Olympus FV500 confocal microscope, and 
images obtained were processed using the Olympus Fluoview software. 
2.4.2.3. Phagocytosis Immunofluorescence Assay.  
Cells were incubated in Opti-MEM (Invitrogen) for 3 h and then treated with ADO 
for 3 h. Green fluorescent protein (GFP) expressing bacteria were then added to the 
cells for 10 min to allow for phagocytosis to occur. The bacteria were then washed off 
by PBS, and the cells were fixed with 4% (w/v) paraformaldehyde on ice for 25 min 
prior to washing with PBS. Fixed cells (200 cells) were randomly selected, and the 
number of bacteria remaining on the coverslip, as well as the number of cells was 
enumerated. The number of bacteria per cell was expressed as a percentage of the 
vehicle control. 
2.4.3. Fluorescence-activated Cell Sorting (FACS) 
2.4.3.1. Quantification of cell surface receptors 
Cells were pretreated with DMSO (0.2% v/v) or ADO, and harvested using 2 mM 
EDTA. Cells were then quantified using a haemocytometer, and 1 x 10
6
 cells from 
each sample were used. Cells were blocked using 0.5 % bovine serum albumin (BSA) 
in PBS for 20 min, and probed with primary antibodies for 1 h, washed, and probed 
with secondary antibodies for 1 h. Cells were washed, fixed with 2% (w/v) 
paraformaldehyde and analysed using the Cytomics FC 500 Series Flow Cytometry 
Systems (Beckman Coulter).  
 





2.4.3.2. Endocytosis Assay 
Cells were first pretreated with DMSO (0.2% v/v) or ADO for 4 h, detached from the 
plate using 2 mM EDTA, and then incubated with anti-EGFR (Clone 29.1, Sigma, 
Singapore) or OKT9 on ice for 1 h. The cells were then washed and replaced in 
complete media with DMSO or ADO and incubated at 37 C. At the appropriate time 
points, remaining surface bound antibody was washed off cells with an acid wash (pH 
2.0). The cells were then fixed with methanol, stained with anti-mouse FITC (Jackson 
ImmunoResearch, West Grove, Pennsylvania, USA) and analysed using the Cytomics 
FC 500 Series Flow Cytometry Systems (Beckman Coulter). The percentage of 
internalised EGFR was calculated by the following formula: mean fluorescence 
intensity from intracellular EGFR/ (mean fluorescence intensity from total EGFR) x 
100. 
 
2.4.3.3. Quantification of intracellular receptors 
Cells were first pretreated with DMSO (0.2% v/v) or ADO for 3 h, fixed for 25 
minutes on ice using 4% (w/v) paraformaldehyde, washed 3 times, followed by 
permeabilization with 0.2% (w/v) saponin in PBS for 30 min at room temperature. 
Cells were then incubated with the appropriate primary antibodies, washed, 
centrifuged, incubated with the appropriate secondary antibodies, washed and 
analysed. 
 





2.4.4. Western Blot Analysis 
2.4.4.1. Steady-state studies 
Cells were pretreated with DMSO (0.2% v/v) or ADO for 4 h, harvested by 2 mM 
EDTA and lysed for 1 h using 1% (v/v) Triton X-100, supplemented with 2x 
complete protease inhibitor cocktail (Roche, Indianapolis, Indianna, USA) and 2 mM 
phenylmethanesulphonylfluoride, in PBS. Protein concentration was read using the 
Bradford assay (Bio-Rad), resolved on an SDS-PAGE gel and transferred to a 
nitrocellulose membrane (Bio-Rad). Blots were then blocked with 5 % (w/v) skimmed 
milk in PBS containing 0.1% (v/v) Tween-20 and probed using the primary antibodies 
and secondary antibodies at room temperature in blocking buffer. The secondary 
antibodies used were either anti mouse or rabbit conjugated horse radish peroxidase 
IgG antibodies (Thermo Scientific), depending on the serotype of the primary 
antibody used. The immunoreactive bands were visualised using chemiluminescent 
substrate (Thermo Scientific) and exposed to X-ray film (Thermo Scientific). The 
resulting blot was then scanned and band signals were quantified using ImageJ and 
normalised to the appropriate control.  
 
2.4.4.2. Kinetics studies 
Cells were incubated on ice with the primary antibody against the protein of interest 
for 1 h, washed, and replaced in complete media with DMSO (0.2% v/v) or ADO, 
incubated at 37 C in the CO2 incubator for varying time-points. Cells were then 
detached from the plate using 2 mM EDTA and lysed. The lysate was then separated 
on a SDS-PAGE gel and transferred onto a nitrocellulose membrane (Bio-Rad). The 
blots were then blocked with 5 % (w/v) skimmed milk in PBS and 0.1% (v/v) Tween-





20 and probed using the appropriate horse radish peroxidise conjugated secondary 
antibody. 
 
2.4.4.3. L-cysteine blocking assay 
ADO was incubated with 5mM L-cysteine in DMEM at 37 °C for 1 h and the 
resultant mixture was added to A-431 cells and incubated for 4 h, before the cells 
were washed, lysed and analysed by Western blot. 
 
2.4.5. Reverse-transcription polymerase chain reaction (RT-PCR) 
Cells were pretreated with DMSO (0.2% v/v) or ADO for 4 h. Total RNA was 
extracted using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. 
First strand synthesis was performed using 7 μg of total RNA, oligo dT primer and M-
MLV Reverse Transcriptase (Promega) following the manufacturer’s instructions and 
polymerase chain reaction (PCR) performed using the GeneAmp PCR System 9700 
(Applied Biosystems) using the following cycling conditions: 
94 °C for 2 min; 94 °C for 15 s, 60 °C for 15 s, 72 °C for 30 s and repeated for 22 
cycles; 72 °C for 5 min. The corresponding PCR product was then analysed by 
agarose gel electrophoresis. 
Primers: EGFR forward primer 5’-ATGCAAATAAAACCGGACTGAAGG-3’ 
  EGFR reverse primer 5’-ACGTGGTGGGGTTGTAGAGCA-3’ 
   β- actin forward primer  
 5’-GAACCCTAAGGCCAACCGTGAAAAGATG-3’ 
  β- actin reverse primer 5’-GGCCAGCCAAGTCCAGACGCAG-3’ 
 





2.4.6. Recycling Assay 
Cells were pretreated with DMSO (0.2 % v/v) or ADO and starved in serum free 
DMEM for 4 h. Cells were then incubated with Alexa Fluor 488 conjugated 
transferrin (Invitrogen) for 1 h in a water bath at 17 ºC in the presence of the 
compound to allow transferrin to be trapped in the recycling compartment.  Residual 
surface transferrin was then washed off with ice cold acetic acid wash (pH 3.5) and 
the cells were then washed with DMEM and PBS. Cells were then replaced in the 
CO2 incubator in PBS, with holo-transferrin and either DMSO or ADO, to allow for 
the trapped transferrin to be recycled. PBS was collected at selected time points and 
the cells in the dish lysed. Amount of fluorescent transferrin in PBS and cell lysates 
was quantified using the microplate reader (Tecan Gemini Infinite 200) using an 
excitation wavelength of 480 nm and emission wavelength of 520 nm. The percentage 
of intracellular transferrin was calculated by the following formula:  
fluorescence from lysate/ (fluorescence from lysate + fluorescence from PBS) x 100. 
2.4.7. Phagocytosis Assay 
2.4.7.1. Vybrant Phagocytosis Assay 
The assay was conducted based on the protocol of the Vybrant phagocytosis assay 
(Invitrogen). Briefly, cells seeded in 96-wells were incubated with 25 µl of either anti-
CD36, or anti-CD204 or anti-MARCO antibodies in media on ice for 1 h in media, 
before 25µl of K-12 fluorescent E. coli bioparticles with the appropriate amount of 
antibodies were added in and allowed to internalise for 1 h at 37 
o
C. The bioparticles 
were removed and trypan blue was added to the wells for 1 min to quench the 
fluorescence of extracellular particles. Trypan blue was then removed and the amount 





of bioparticles engulfed by cells measured using the Tecan Gemini Infinite 200 plate 
reader using 480nm for excitation and 520nm for emission.   
2.4.7.2. Suspension Phagocytosis Assay 
Cells were treated with varying concentrations of ADO for 3 h, then incubated with 
fixed green fluorescent protein (GFP) expressing bacteria and ADO for 10 min. The 
mixtures were washed with PBS, spun down at 1500 rpm for 5 min at 4 
o
C and fixed 
in 2% (w/v) paraformaldehyde for 30 min. The amount of internalised bacteria was 
read using the Cytomics FC 500 Series Flow Cytometry Systems (Beckman Coulter) 
with gating for cells. 
 
2.4.8. p38 MAP Kinase assay 
Cells were starved overnight in serum-free DMEM, and then treated with ADO for 4 
h, or 100ng/ml recombinant EGF for 15 min. Cells were then rinsed 1x with cold PBS 
and processed according to the instructions in the p38 MAP kinase assay kit (Cell 
Signalling Technology, Beverley, Massachusetts, USA). Briefly, cells were lysed and 
immunoprecipitated with immobilized phospho-p38 MAPK antibody overnight. The 
beads were washed and then incubated with ATF-2 fusion protein and ATP for 30 
min at 30 °C to allow for p38 MAPK to phosphorylate ATF-2. Levels of 
phosphorylated ATF-2 was then detected using western blot analysis. 
 
2.4.9. CD204 secretion assay 
Cells were seeded overnight in a 96-well plate, washed once in OPTI-MEM, and then 
treated in OPTI-MEM with ADO for 8 h. Cells were then dislodged by 2 cycles of 
incubation with 2 mM EDTA for 10 min followed by 5 times of washing. Secreted 





CD204 was then fixed with 4% (w/v) paraformaldehyde for 20 min followed by 
washing. Wells were then blocked overnight with 10 %(w/v) BSA in PBS. Wells 
were then rinsed with 0.05% (v/v) Tween-20 in PBS, and 2 µg/ml anti-CD204 
antibody was then added for an hour. Primary antibody was then rinsed off with 0.05% 
(v/v) Tween-20 and 1:500 anti-rat Cy3-conjugated secondary antibody was added for 
1 h. Excess secondary antibody was then rinsed off and the plate was read using the 
Tecan Gemini Infinite 200 plate reader using 555nm for excitation and 580nm for 
emission. 
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3. Andrographolide affects receptor trafficking in A-431 cells 
 
3.1. Abstract 
ADO, an active component of Andrographis paniculata, is known to affect the levels 
of cell surface receptors present on dendritic cells after activation with 
lipopolysaccharide. Hence, we were interested to investigate if ADO could affect 
receptor trafficking in general. We used the epidermoid carcinoma cell line, A-431, as 
a model as it over-expresses two receptors which have different trafficking pathways. 
The epidermal growth factor receptor (EGFR), is known to endocytose and move to 
the lysosomes for degradation, whereas the transferrin receptor (TfR) endocytoses and 
recycles constitutively back to the cell surface. We found that ADO changed the 
degradation rates of EGFR and TfR; it decreased surface levels of EGFR through 
increasing EGFR internalisation, and accumulated EGFR in a lysosomal associated 




ADO is the main active constituent of the plant Andrographis paniculata. This 
versatile compound has been found to have hepatoprotective effects  against toxic 
substances (Sheeja & Kuttan, 2006), and it is also anti-inflammatory in nature, as it 
can suppress inflammation by inhibiting the nuclear translocation of NF-κB (Singha 
et al., 2007; Bao et al., 2009). Previously, it has also been demonstrated to be an anti-
cancer compound, as it can cause apoptosis in hepatocellular carcinoma cells (Yang et 
al., 2009b), as well as induce cell cycle arrest in colorectal carcinoma cells (Shi et al., 
2008). Furthermore, ADO affects dendritic cell maturation by inhibiting the 







, CD40 and CD86 upon lipopolysaccharide induction of dendritic 
cells (Iruretagoyena et al., 2005). This suggested that ADO may have an effect on the 
trafficking of these molecules to the cell surface, and thus we hypothesised that the 
anti-neoplastic effect of ADO could be due to the ability of ADO in regulating cell 
surface expression and trafficking of growth-regulating receptors such as the 
epidermal growth factor receptor (EGFR) and the transferrin receptor (TfR). These 
two receptors are of interest as both are known to be upregulated in cancers. In 
particular, EGFR has been known to be upregulated in various cancers involving the 
head and neck (Gold et al., 2009), lung (Dy & Adjei, 2009), gliomas (Kesari et al., 
2006) and ovaries (Lafky et al., 2008); while TfR is known to be overexpressed in 
breast cancer (Habashy et al., 2009). As such, EGFR and TfR have become prime 
targets in the development of cancer therapies (Lepelletier et al., 2007; Capdevila et 
al., 2009), and hence they are also the focus of our current study. In addition, these 
two receptors follow different pathways upon internalisation into the cell. Hence, 
observations of the effects of ADO on these two receptors would be useful in the 
detection of how ADO may differentially affect trafficking of these receptors within 
the cell. Furthermore, the trafficking of these receptors have been extensively studied, 
making it much easier to establish the membrane compartments which ADO affects. 
 
3.2.1. Epidermal Growth Factor Receptor (EGFR) 
EGFR is a 170 kDa transmembrane receptor tyrosine kinase that has been extensively 
characterised. It is an important player in activating signaling pathways for cell 
growth. In its inactive state, it is known to localise on the plasma membrane to 
cholesterol-rich lipid rafts, which are detergent resistant regions that are distinct from 
caveolae (Pike, 2005). Upon the binding of EGF to EGFR, the tyrosine kinase 





receptors dimerize and autophosphorylate, forming the active state where it triggers 
the Ras- mitogen associated protein kinase (MAPK) pathway for cell proliferation. 
The receptors are then internalised into the cells for downregulation. In the classical 
pathway, upon the dimerization and phosphorylation of the receptors, they move into 
clathrin coated pits. Cbl, a ubiquitin E3 ligase, then binds at and ubiquitinates the 
receptors and the proteins associated with EGFR, epsin and EPS15 (Le Roy & Wrana, 
2005). The ubiquitination of EGFR is important for the sorting of the receptors to the 
endosomes for degradation. Upon entry into the cell, the receptor then moves to the 
early endosomes. It is then either recycled back up to the cell surface, or moves to the 
multi vesicular body (MVB) and then to the late endosomes and lysosomes for 




The notion that EGFR is capable of clathrin independent endocytosis has been 
explored in various studies recently. Caveolae, which are lipid rich rafts with 
associated caveolin-1 and the absence of clathrin, were found to contain EGFR 
(Sigismund et al., 2005). However, although EGFR is associated with caveolae, there 
is no concrete evidence to demonstrate that caveolae are important for EGFR 
internalisation (Sigismund et al., 2008; Madshus & Stang, 2009). Another clathrin 
independent mode of EGFR internalisation is via circular dorsal ruffles, which 
recruits large amounts of surface EGFR into membrane ruffles with the aid of 
dynamin, phosphatidylinositol-3-kinase and EGFR activation (Orth et al., 2006; Orth 
& McNiven, 2006). This mode of internalisation usually occurs in the presence of 
high amounts of EGF (30 ng/ml). Although EGFR can be internalised in a clathrin-





independent manner, the primary mode of internalisation is likely to be mainly via 
clathrin coated pits as it is the most rapid mode of internalisation (Sorkin & Goh, 
2009).  
 
3.2.2. Transferrin Receptor 
TfR, is a 95kDa transmembrane receptor that is one of the important proteins involved 
in the uptake of iron (Daniels et al., 2006). Two TfR binds transferrin, which binds to 
two ferric ions, and like EGFR, is endocytosed in clathrin-coated pits. It then moves 
to the sorting endosomes, where the iron ions are released due to the lower pH of the 
endosomes, to the endocytic recycling compartment, and back to the plasma 
membrane (Maxfield & McGraw, 2004). TfR was chosen as a marker of the recycling 
pathway as it is known to constitutively recycle. 
 
The aim of this part of the work is to elucidate the effects of ADO on receptors 
critical for cell proliferation and survival in the human epidermoid carcinoma A-431 
cells. A-431 was chosen as it is a cancer cell line, and it expresses our receptors of 
interest at high levels – epidermal growth factor receptor (EGFR) (Wrann & Fox, 
1979) and transferrin receptor (TfR) (Hopkins & Trowbridge, 1983). In this study, we 
show that ADO causes the downregulation of EGFR from the cell surface as well as 
the inhibition of EGFR and TfR degradation. 






3.3.1. Andrographolide inhibits growth and downregulates surface EGFR  
 
In order to understand the effect of ADO on cell proliferation, A-431 cells were 
exposed to varying concentrations of ADO for 24 h and analysed by the MTT 
cytotoxicity assay. As expected from previous work on several other cancer cell lines 
such as colon cancer (Rajagopal et al., 2003; Kumar et al., 2004), prostate cancer 
(Kim et al., 2005), liver cancer, (Li et al., 2007), leukaemia (Cheung et al., 2005), 
cervical cancer (Zhou et al., 2006), and promyelocytic leukaemia cells (Manikam & 
Stanslas, 2009), ADO could inhibit cancer cell growth. In our experiment, growth of 
A-431 was inhibited significantly from 60 μM onwards (Figure 3.1). Since EGFR is 
known to be one of the receptors important for cell growth and proliferation of cancer 
cells, we went on to investigate if surface levels of EGFR were affected upon 
treatment with ADO at concentrations and incubation times that are not known to 
cause apoptosis. This was to ensure that the effects observed on EGFR are specific to 
ADO, and are not due to downstream events from apoptosis. Approximately 30% of 
surface EGFR was downregulated upon ADO treatment at both 50 µM and 100 µM 
(Figure 3.2). Similarly, downregulation of approximately 30% of surface EGFR also 
occurs for treatment of A-431 at concentrations of 5 µM and 15 µM ADO for 48 h 
(Figure 3.3). The longer timepoint of 48 h was chosen to ensure that the effects of 
ADO were also true at lower doses. 
 
  












VC    5 μM ADO       15 μM ADO 
 
Figure 3.1 Assessment of cell viability upon ADO treatment. A-431 cells were treated 
with varying concentrations of ADO for 24h, and cell viability assessed by MTT assay. Values 
from each concentration were compared to the untreated cells and expressed as mean ± standard 
deviation from two independent experiments. Vehicle control, VC; andrographolide, ADO. * P 
<0.05 relative to vehicle control. 
 
Figure 3.2 Surface expression of EGFR after ADO treatment. A-431 cells were treated 
with various concentrations of ADO for 4 h and then analysed by flow cytometry for surface 
EGFR. Mean fluorescence intensity of surface receptor levels is expressed as a percentage of 
vehicle control (VC) ± SD of at least two experiments. Vehicle control, VC; andrographolide, 
ADO.  *P < 0.05 relative to vehicle control. 
 
Figure 3.3 Surface expression of EGFR after 48 h of ADO treatment. A-431 cells were 
treated with various concentrations of ADO for 48 h and then analysed by flow cytometry for 
surface EGFR. Mean fluorescence intensity of surface receptor levels was expressed as a 
percentage of vehicle control (VC), ±SD of at least two experiments. Vehicle control, VC; 
andrographolide, ADO. *P < 0.01 relative to vehicle control. 





Since surface EGFR was downregulated by ADO, it was possible that ADO could 
have decreased the total amount of EGFR in A-431 cells. However, as shown in A-
431 cells treated with ADO for 4 h and analysed by western blot (Figure 3.4), the total 
amount of EGFR was not decreased, but significantly increased by around 15% upon 
treatment with 100 µM ADO.  
  
In order to ascertain if the change in total amount of EGFR was due to increase in 
EGFR mRNA transcripts, total RNA was extracted from cells treated with 50 µM and 
100 µM ADO for 4 h and analysed by RT-PCR. From the results, it is evident that 
there was no change in the amount of EGFR mRNA at the transcriptional level 
(Figure 3.5).  
  





Figure 3.4 Western blot analysis of ADO effect on total EGFRs in A-431. A-431 cells 
were treated with various concentrations of ADO for 4 h and then analysed by Western blot for 
total EGFRs. Blots are representative of at least two experiments. Intensity of Western blot bands 
were quantified and normalised to β-actin, then expressed as a percentage of VC ± SD of at least 
two experiments. Vehicle control, VC; andrographolide, ADO. *P < 0.005 relative to vehicle 
control . 
Figure 3.5 Reverse-transcription polymerase chain reaction (RT-PCR) of EGFR 
mRNA transcripts. A-431 cells were treated with various concentrations of ADO for 4 h and 
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3.3.2. Andrographolide changed the rate of degradation of both EGFR and 
TfR 
 
As the ADO-induced upregulation of EGFR was not due to an increase in EGFR 
mRNA transcripts, it is possible that ADO inhibits trafficking of EGFRs to the 
lysosomes for degradation in A-431 cells. To determine whether this occurs, surface 
EGFRs of A-431 cells were labelled with mouse EGFR-specific monoclonal antibody 
and internalised into the cell at various time points either in the presence or absence of 
ADO. Cells were then lysed and analysed by Western blot using horse radish 
peroxidise conjugated anti-mouse antibodies to detect the heavy and light chain of the 
EGFR-specific antibodies. The degradation rate of the EGFR-specific antibodies was 
used as a marker for determining the rate of EGFR trafficking to the late lysosomes 
for degradation. Significant changes in the degradation rate upon ADO treatment were 
observed at 3 and 4 h (Figure 3.6A, lanes 4–7, and B), and degradation was  inhibited 
by approximately 22%. Thus, ADO delayed trafficking of EGFRs from the cell 
surface to the lysosomes for degradation. To ascertain whether this inhibition of 
degradation was specific for EGFR or if it affects general receptor trafficking from 
the cell surface, a similar degradation assay for TfR was run with anti-TfR antibody.  
  
Interestingly, TfR degradation was inhibited significantly at 4 h and up to 
approximately 47% at 6 h (Figure 3.7A, lanes 4–7, and B). Thus, our results indicate 
that ADO induces the accumulation of both EGFRs and TfRs in intracellular 
membrane compartments of A-431 cells. 
  





A. Figure 3.6 ADO changed the rate of degradation of EGFR. A-431 cells were 
incubated with primary antibody on ice for 1 h, treated with DMSO or ADO for the various 
time points at 37°C and then subjected to Western blot analysis for IgG; β-actin was used as 
a loading control. Blots are representative of at least three experiments. The intensity of the 
Western blot bands were quantified and normalised to β-actin, and expressed as a percentage 
of the initial amount of antibody at 0 h ± SD of at least two experiments (A and B). 
Internalised EGFR was degraded more slowly in ADO-treated cells. VC, vehicle control; 
ADO, andrographolide, EGFR, epidermal growth factor receptor; . 
 
A. Western blot of internalised EGFR.  



















Figure 3.7 ADO changed the rate of degradation of TfR. A-431 cells were incubated 
with primary antibody on ice for 1 h, treated with DMSO or ADO for the various time points at 
37°C and then subjected to Western blot analysis for IgG; β-actin was used as a loading control. 
Blots are representative of at least three experiments. The intensity of the Western blot bands 
were quantified and normalised to β-actin, and expressed as a percentage of the initial amount of 
antibody at 0 h ± SD of at least two experiments (A and B). Internalised TfR accumulated in 
ADO-treated cells although degradation is not inhibited. VC, vehicle control; ADO, 
andrographolide, TfR, transferrin receptor. 
 
B. Western blot of internalised TfR.  




















3.3.3. Andrographolide induced the accumulation of EGFRs into an 
intracellular LAMP-1- and VAMP-8-positive but VAMP-3-negative 
membrane compartment 
 
The intracellular localisation of cell surface internalised EGFR and TFR in A-431 
cells upon ADO treatment was examined by immunofluorescence microscopy. A-431 
cells were treated with ADO for 4 h, fixed and then stained for EGFR. As can be seen, 
EGFR accumulates in compact membrane structures in the perinuclear region, and 
this effect is slightly more apparent upon 100 µM ADO treatment (Figure 3.8A, panel 
c). Upon the addition of EGF, which was utilised to drive the surface EGFR into the 
cell, the ADO induced accumulation of EGFR became more pronounced in 
comparison to the vehicle control (Figure 3.8A, panels e and f). Similarly, internalised 
surface EGFR is also accumulated at the perinuclear region upon treatment with 5 µM 
and 10 µM of ADO for 28 h (Fig. 3.8B). 
 
To confirm that the EGFR accumulated at the compact structures are originated from 
the cell surface and not newly synthesised EGFR which were retained in intracellular 
compartments such as the Golgi, surface EGFR of A-431 cells were labelled with 
anti-EGFR antibody, internalised into the cell for various time points in the absence or 
presence of ADO, fixed and analysed by immunofluorescence microscopy. As 
anticipated, the perinuclear compact membrane structure (PCM) was also apparent 
(Figure 3.8C), thus showing that the EGFR accumulated at the perinuclear compact 
structure in the presence of ADO are cell surface EGFR internalised from the cell 
surface.  
 





Figure 3.8 ADO affected the intracellular distribution of EGFRs.  
A. A-431 cells were treated with various concentrations of ADO for the 4 h in the presence or absence of 100 
nM EGF, then fixed and stained with antibody (29.1) against EGFR. Scale bars are representative of 10 
μm. 
B. Effect on EGFR by ADO internalised from the cell surface for 4 h after 24 h treatment Scale bars are 
representative of 10 μm. 
C. Effect on EGFR by ADO internalised from the cell surface for various treatment timepoints. Scale bars are 
representative of 10 μm. 
VC, vehicle control; ADO, andrographolide; EGFR, epidermal growth factor receptor; EGF, epidermal 
growth factor. 
  





Co-localisation studies were then carried out to determine the compartment that 
EGFR is accumulated in. Under steady-state conditions, where A-431 cells were 
treated with ADO for 4 h and then fixed and stained for EGFR together with a 
compartmental marker, EGFR did not co-localise well with the vesicle associated 
membrane protein-3 (VAMP-3) in both cells treated with ADO without (Figure 3.9, 
panels a-i) and with EGF (Figure 3.9, panels j-r) even though there was some overlap 
in EGFR and VAMP-3 antibody staining. This is as the shape of the structures 
staining for VAMP-3 and the ADO induced EGFR clump is different. Confocal 3D 
convolution and XZ/YZ projection imaging further confirmed that EGFR and VAMP-
3 do not co-localise in the PCM structures (Figure 3.10). VAMP-3 is a soluble NSF 
attachment receptor (SNARE) that resides within the early and recycling endosomes 
(Hong, 2005). The co-localisation of EGFR was better with vesicle associated 
membrane protein -8 (VAMP-8) (Figure 3.11), a SNARE that resides in both the early 
and late endosomes (Wong et al., 1998; Antonin et al., 2000) in A-431 cells. As can 
be seen, EGFR in both the vehicle control and ADO treated cells have structures that 
are similar to VAMP-8.   





Figure 3.9 Intracellular distribution of EGFRs in ADO treated cells. A-431 cells were treated 
with various concentrations of ADO for the 4 h in the presence or absence of 100 nM EGF, then fixed and 
stained with antibody against EGFR and co-localised with VAMP-3. Scale bars are representative of 10 
μm. Arrows point to the overlapping EGFR and VAMP-3 compartments. VC, vehicle control; ADO, 
Andrographolide; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor. 
 
Figure 3.10 X-Z/Y-Z projection of EGFR with VAMP-3 after ADO treatment. A-431 cells were 
incubated with anti-EGFR on ice, treated with 100 µM ADO for 4 h at 37°C, and then fixed and stained with anti-
VAMP-3 antibody. Photomicrographs are representative of at least two independent experiments, and were taken 
with the Olympus FV 1000 confocal microscope at 100x magnification. Scale bars represent 10 µm. Arrows point to 
the lack of co-localization between EGFR and VAMP-3. VC, vehicle control; ADO, Andrographolide; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor. 
 





Similar results were also obtained for TfR. A-431 cells treated with ADO for 4 hours 
which were then fixed and stained for TfR show that TfR accumulates at the PCM 
structures (Figure 3.12A, panel c). Similarly, TfR forms a clump under steady state 
conditions upon treatment with 5 µM and 10 µM ADO for 24 h (Fig. 3.12B, panels b 
and c). Internalised surface TfR (labelled with anti-TfR antibody) was also found to 
accumulate at the perinuclear region upon ADO-treatment (Figure 3.12C, panels d 
and f). Cells were then treated with ADO under steady state conditions for 4 h, fixed 
and stained for TfR, together with either VAMP-3 and VAMP-8. We observed that 
TfR co-localises well with VAMP-8 (Figure 3.12E), but did not co-localise as well 
with VAMP-3 (Figure 3.12D) in the PCM structures.  
  














Figure 3.11 ADO enhances EGFR co-localization with VAMP-8. A-431 cells were 
incubated with primary antibody on ice, treated with 100 µM ADO for 4 h, fixed and stained with 
VAMP-8 antibody. The perinuclear clump of EGFRs co-localised well with VAMP-8 for both 
vehicle control (VC) and ADO treatment. Inset image shows enlarged image of EGFR and 
VAMP-8 co-localisation. Scale bars are representative of 10 μm. VC, vehicle control; ADO, 
andrographolide. EGFR, epidermal growth factor receptor. 
 





Figure 3.12 ADO affected intracellular distribution of TfRs. ADO affected the intracellular 
distribution of TfRs. A-431 cells were treated with various concentrations of ADO for 4 h (A), or 24 h (B), 
then fixed and stained with antibodies; or they were incubated with primary antibody on ice, and then treated 
with various concentrations of ADO at 37°C, fixed and stained (C, D, E). Primary antibodies used were 
against TfR (monoclonal), VAMP-3 (polyclonal), and VAMP-8 (polyclonal), and secondary antibodies were 
FITC-conjugated anti-mouse IgG and Cy-3 conjugated anti-rabbit IgG. Photos are representative of at least 
two independent experiments, and were taken with the Olympus BX60 (A, B, C, E) and Leica TS5 confocal 
microscope (D) at 100x magnification. Scale bars represent 10 µm.  
 
A. Effect of ADO on steady state TfRs after the 4 h treatment. 
B. Effect of ADO on steady state TfRs after the 24 h treatment. 
C. Effect of ADO on TfRs internalised from the cell surface. The time points tested were 2 h and 4 h.  
D. The perinuclear clump of TfRs did not co-localise well with VAMP-3. 
E. The perinuclear clump of TfRs co-localised well with VAMP-8. Inset image shows enlarged image of 
TfR, VAMP-8 co-localisation. Vehicle control, VC; andrographolide, ADO. EGFR, epidermal growth 
factor receptor; TfR, transferrin receptor; VAMP, vesicle-associated membrane protein. 
  





 In order to further characterise the compartment which EGFR is present in upon 
andrographolide treatment, surface EGFR of A-431 cells were labelled with Alexa 
Fluor-conjugated EGF, internalised, fixed at various time-points and then co-localised 
with lysosomal associated membrane protein-1 (LAMP-1), a commonly used marker 
for late endosomes and lysosomes (Eskelinen et al., 2003). As can be seen, EGFR is 
present in the PCM structures in ADO treated cells at the 2 and 4 hours time-point 
(Figure 3.13A, panels j and p). This is consistent with the earlier result which 
demonstrates that EGFR degradation is inhibited upon ADO treatment (Figure 3.6). 
Internalised EGF also co-localised well with LAMP-1 at 2 and 4 hour time-points in 
the presence of ADO (Figure 3.13A, panels l and r). Furthermore, confocal 3D 
convolution and X-Z/Y-Z projection imaging showed that co-localisation between 
EGF and LAMP-1 in the PCM structures occurs both for the vehicle control (though 
to a lesser extent) and ADO-treated cells (Figure 3.13B, C). This is not surprising as it 
has been known that EGFR trafficked to the late endosomes and lysosomes for 
degradation (Le Roy & Wrana, 2005). Hence, this demonstrates that ADO 
accumulates EGFR in the late endosomes and lysosomes.  





Figure 3.13 Epidermal growth factor receptor (EGFR) accumulated in an intracellular membrane 
compartment that co-localises with LAMP-1 upon treatment with ADO. Cells were incubated with 
labelled EGF on ice, treated with various concentrations of ADO, then fixed and stained with antibody against 
LAMP-1 (monoclonal). Photos are representative of at least two independent experiments. Vehicle control, VC; 
andrographolide, ADO. 
 
A. Internalised labelled EGF co-localised with LAMP-1. The time points tested were 2 h and 4 h. Images were 
taken using Olympus BX60. Scale bars represent 10 µm. 
B. Stereo three-dimensional convolution image of EGF co-localisation with LAMP-1. Images were taken 
using the confocal microscope Olympus Fluoview 500. Stereo three-dimensional rendering was performed 
using the volocity visualization software from Improvision. Scale bar represents 5 µm. Arrowheads point to 
co-localization between EGFR and LAMP-1 
C. X-Z/Y-Z projection of EGF co-localisation with LAMP-1. Images were taken using Olympus Fluoview 
500. X-Z/Y-Z projection was performed using the volocity visualization software from Improvision. Scale 
bar represents 12 µm. LAMP-1, lysosomal-associated membrane protein-1. Arrow points to the co-









3.3.4. Downregulation of surface EGFR upon andrographolide treatment was 
not due to the inhibition of receptor recycling but due to the enhanced 
internalisation of EGFR from the cell surface of A-431 cells  
 
In view of our observation that ADO downregulates expression of cell surface EGFR 
and accumulates EGFR in intracellular membrane compartments, there is a possibility 
that ADO could also regulate recycling of EGFR to the cell surface in A-431 cells. 
The recycling pathway is responsible for recycling receptors from the endocytic 
recycling compartment back to the cell surface (Maxfield & McGraw, 2004), and 
therefore inhibition of this pathway could act as a contributing factor to the inhibition 
in degradation of both EGFR and TfR. To examine this possibility, cells were serum 
starved and either untreated or pretreated with ADO for 4 h. Cells were then 
incubated with labelled transferrin for 1 h, washed and then further incubated for 
various time-points prior to media collection and quantification of recycled labelled 
transferrin. TfR is utilised here as a marker for the recycling pathway as it is 
constitutively recycled back to the cell surface. As can be seen, ADO did not 
significantly affect the recycling of TfR (Figure 3.14A, panel a) from the time-points 
of 0 to 90 minutes.  
 
It was also possible that the change in the level of cell surface EGFR was due to a 
change in the rate of receptor internalisation into the cell. Hence, the rate of receptor 
internalisation was quantified by incubating cells with ADO for 4 h. Cell surface 
receptors were then incubated with anti-EGFR antibody for an hour on ice. Anti-
EGFR antibody was then allowed to internalise by replacing cells in media and 
incubating them at 37 ºC. At each time-point, the cells were washed with acid wash to 





remove anti-EGFR antibody remaining on the cell surface. Cells were then fixed and 
stained with FITC-conjugated secondary antibodies and the amount of intracellular 
anti-EGFR antibody was then quantified by flow-cytometry. Interestingly, ADO was 
found to enhance the rate of EGFR internalisation from the cell surface (Figure 3.14A, 
panel b). The increase in the rate of internalisation of EGFR accounts for the decrease 
in the amount of surface EGFR upon ADO treatment. However, it is worth noting that 
the effect of ADO on receptor internalisation seen here is EGFR-specific, as ADO 
does not significantly enhance internalisation of TfR from the cell surface (Figure 
3.14A, panel c) 
 
It was then interesting to find out if ADO could induce phosphorylation of EGFR so 
as to increase the internalisation rate, as EGFR is known to be endocytosed upon 
activation. Serum starved cells were treated in two separate groups – one group was 
pretreated with ADO for 4 hours, the other group was induced with EGF for 15 
minutes. Both groups were then detached and lysed and analysed by western blot for 
activated EGFR. ADO did not change the phosphorylation levels of EGFR (Figure 
3.14B).  





Figure 3.14 Andrographolide (ADO) did not affect the recycling pathway, but increased the 
internalisation of EGFR 
 
A. (a) A-431 cells were pretreated with DMSO or 100 mM ADO for 4 h in serum-free DMEM, and 
then incubated with Alexa Fluor 488 labelled transferrin at 17°C. Unbound transferrin was then 
washed off and internalised transferrin allowed to recycle for 0–90 min. The amount of unrecycled 
transferrin in the cells was quantified and expressed as a percentage of total bound transferrin. 
Results are expressed as a mean percentage ± SD from two independent experiments. (b) ADO 
increased the internalization of EGFR. A-431 cells were pretreated with DMSO or 100 µM ADO 
for 4 h, and then incubated with anti-EGFR on ice for 1 h, before being placed in media and fixed 
at various time points. Cells were then stained with FITC-conjugated anti mouse IgG and read with 
the flow cytometer. Results are expressed as a percentage of the total amount of EGFR on the cell 
surface ± SD from two independent experiments. * P <0.05 relative to vehicle control. (c) ADO did 
not increase the internalization of TfR. A-431 cells were pretreated with DMSO or 100 µM ADO 
for 4 h, and then incubated with anti-TfR on ice for 1 h, before being placed in the media and fixed 
at various time points. Cells were then stained with FITC-conjugated anti-mouse IgG and read with 
the flow cytometer. Results are expressed as a percentage of the total amount of TfR on the cell 
surface ± SD from two independent experiments. VC, vehicle control; ADO, andrographolide; 
EGFR, epidermal growth factor receptor; TfR, transferrin receptor. 
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Figure 3.14 ADO did not affect the recycling pathway, but increased the internalization 
of EGFR 
B. ADO did not induce the phosphorylation of EGFR.For the EGF group, A-431 cells were 
deprived of serum and then treated with various concentrations of EGF for 15 min. For the 
ADO group, A-431 cells were deprived of serum and treated with DMSO or ADO for 4 h, then 
lysed and used for Western blot analysis. Blots were probed for activated EGFR; β-actin was 
the loading control. The intensity of the activated EGFR bands was quantified, normalised to 
β-actin bands, and expressed as a percentage of the control ± SD of at least two experiments. 
Blots are representative of at least two experiments. (a) Western blot of phosphorylated EGFR. 
(b) Quantification of phosphorylated EGFR. VC, vehicle control; ADO, andrographolide; 
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Thus far, no work has been carried out to determine if ADO modulates receptor 
trafficking, particularly receptors that are implicated in cancer progression like EGFR 
and those important for cell survival like TfR. Here, we demonstrate that ADO can 
affect receptor trafficking. Although the concentration of ADO utilised in this paper is 
higher than the concentration used in most papers, the effect of ADO observed on A-
431 cells at 100 µM for 4 h similarly occurs at 5 µM or 10 µM upon 24 h treatment. 
We have also observed downregulation of close to 30% of cell surface EGFR at 5 µM 
of ADO for 48 h (Figure 3.3), as well as the formation of the PCM for EGFR and TfR 
using 5 µM and 10 µM for 24 h (Figure 3.8B, Figure 3.12B). Thus, it is possible to 
conclude that the effect of ADO at a higher concentration for a shorter time point is 
similar to the lower concentration for a longer time point.  We have chosen to work 
with a shorter time-point and a higher concentration to ensure that the effects 
observed on receptor trafficking are not downstream events of cells dying due to long 
hours of drug treatment. In comparison to other studies, the effects of ADO on EGFR 
and TfR at 10 µM upon 24 h treatment is similar to the concentrations of ADO 
utilised on human colorectal carcinoma Lovo cells (Shi et al., 2008) to inhibit cell 
growth, and is also much lower than 50 µM treatment for 24 h used to induce 
apoptosis in Hela and HepG2 cells (Zhou et al., 2006). Hence, the effects of ADO on 
receptor trafficking are most probably events that are not downstream effects of cell 
death.  
 
Comparisons of the effective concentrations on EGFR and TfR at 24 h to those found 
in in vivo pharmacokinetics studies using normal therapeutic dosages reveal that it 





may be necessary to use higher dosages of ADO to see the anti-cancer effect in vivo. 
This is as plasma concentrations of ADO in humans treated with Kan Jang at the daily 
therapeutic dosage of 1 mg ADO/ kg body weight/ day, which is an approximation of 
60 mg of ADO, gave a peak of 3.8 µM (Panossian et al., 2000), which is slightly 
lower than the effective concentrations of 5 and 10 µM. But it is possible to attain 
much higher plasma concentrations than the 3.8 μM achieved with a higher dosage as 
preliminary pharmacokinetics studies in mice treated at 150 mg ADO/kg have been 
found to yield maximal plasma concentrations of 20 µM to 30 µM (Stanslas et al., 
2001b). However, in the process of dosage optimisation to achieve the anti-cancer 
effect of ADO, it is important to bear in mind results from previous clinical trials and 
toxicity tests. The LD50 of ADO in mice was found to be more than 4000 mg 
ADO/kg/day (Chen et al., 2009), while a small clinical trial conducted in both HIV 
positive and negative volunteers utilising higher dosages of 5 mg ADO/kg body 
weight and 10 mg ADO/ kg body weight 3 times a day to test for toxicity did show 
some adverse effects in the form of rash and diarrhoea, but did not affect liver 
enzymes – aspartate transaminase (AST) and alanine transaminase (ALT) levels 
significantly in normal subjects during the medication period (Calabrese et al., 2000). 
Hence, dosage optimisation within the range of 60 mg to 300 mg daily is needed to 
achieve the anti-cancer effects of ADO in humans without adverse effects.  
 
Here, we have demonstrated that ADO downregulates cell surface EGFR and also 
inhibits the degradation of both EGFR and TfR, causing them to accumulate in the 
late endosomes (Figure 3.15). Upon activation with its ligand, EGFR self-
phosphorylates and is internalised at an increased rate from the cell surface upon 





ADO treatment (Figure 3.14A, panel b), where it moves into the early endosomes and 
progresses to the late endosomes. Interestingly, from our observations, the 
downregulation of cell surface EGFR is not dose-dependent (Figure 3.2). It may be 
possible that the effect of ADO on the trafficking machinery involved in internalising 
cell surface EGFR is saturated at 50 µM for 4 h and 5 µM for 48 h. In the presence of 
ADO, the degradation of EGFR is slowed down such that it accumulates in the 
VAMP-8 positive compartment. Similarly, TfR constitutively internalises from the 
cell surface where it either enters the recycling endosomes to travel back to the 
plasma membrane, or it enters the late endosomes. Upon entry to the late endosomes, 
it also accumulates in a VAMP-8 positive compartment in the presence of ADO, 
similar to EGFR (Figure 3.15). It can be inferred that the VAMP-8 and LAMP-1 
positive compartment that EGFR is accumulated in is the late endosomal 
compartment, as VAMP-8 is known to be found in both early and late endosomes 
(Antonin et al., 2000), whereas LAMP-1 is expressed in both the late endosomes and 
lysosomes (Eskelinen et al., 2003). The accumulation of EGFR in the late endosome 
is expected as EGFR traffics rapidly from the cell surface into the late endosomes for 
degradation upon internalisation. Here, we propose that ADO acts in two ways to 
cause the accumulation of receptors – the increase in the internalisation rate of EGFR 
from the cell surface, and also the inhibition of movement into the lysosomes from 
late endosomes for degradation. The increase in internalisation rate is not the sole 
reason for receptor accumulation as TfR does not internalise more rapidly upon 
treatment, but its degradation is inhibited. Hence, the inhibition in the movement of 
receptors into the lysosomes is more likely to be a greater contributor. In addition, we 
have also ruled out the possibility that ADO inhibits some lysosomal enzymes upon 
treatment for 4 h (data not shown), although it is possible that the endosomal sorting 





complex required for transport (ESCRT) machinery, which is responsible for receptor 
downregulation by trafficking receptors from the endosomes/ multivesicular bodies to 
the lysosomes (Kirisits et al., 2007; Saksena & Emr, 2009), is affected by ADO. Both 
EGFR and TfR also differ at the time-point where the accumulation of receptors is 
obvious (Figure 3.6, 3.7). This most likely due to the difference in the pathways in 
EGFR and TfR, as EGFR is delivered directly for degradation after internalisation, 
whereas a large pool of TfR undergoes a few rounds of recycling to the cell surface 
before being sent for degradation (Daniels et al., 2006). Hence, it would take a longer 
time for TfR accumulation to be obvious. TfR accumulation was also more distinct as 
it took longer for it to be degraded, hence the cells could be treated for 6 h. 
  






Figure 3.15 Proposed mechanism of andrographolide (ADO)-induced inhibition of receptor 
degradation in late endosomes. Monomeric EGFR dimerizes upon binding of a ligand, following which 
the tyrosine kinases autophosphorylate, and enter the cell by endocytosis. Similarly, TfR enters the cell by 
endocytosis constitutively, and a portion of both EGFR and TfR receptors are recycled back to the surface. 
Receptor trafficking from the late endosome to the lysosome is inhibited after ADO treatment. EGFR, 
epidermal growth factor receptor; TfR, transferrin receptor. 





The inhibition of protein trafficking to the lysosome for degradation is detrimental to 
cell survival (Figure 3.1). Lysosomes are acidic, hydrolase containing organelles in 
the cell responsible for protein degradation and recycling (Eskelinen et al., 2003), and 
proteins are trafficked to lysosomes either from autophagosomes or late endosomes 
(Nixon et al., 2008). Failure to efficiently break down proteins targeted for 
degradation is known to be associated with the disruption of cellular function. 
Recently, it was shown that the inhibition of rhodopsin trafficking to lysosomes 
resulted in its accumulation in late endosomes. This accumulation caused the death of 
photoreceptor cells, leading to blindness (Chinchore et al., 2009). Hence, inhibiting 
protein trafficking to the lysosome is a possible mechanism for ADO to induce cell 
death. 
 
It may also seem paradoxical that ADO inhibits cell growth despite the accumulation 
of internalised EGFR (Figure 3.6), as lysosomal degradation is thought to be one of 
the modes of downregulating EGFR mediated signalling. However, it has been 
demonstrated in MDA-MB-468 breast cancer cells, which overexpress EGFR, that 
internalised EGFR is capable of activating caspase-3 to induce cell death (Hyatt & 
Ceresa, 2008). As A-431 is known to express caspase-3 (Mese et al., 2000), it is 
possible that the accumulation of EGFR in the late endosomes by ADO may then 
result in cell death by the activation of caspase-3. 
 
Finally, the downregulation of surface EGFR upon ADO treatment (Figure 3.2) due to 
the increase in the rate of internalisation of receptors (Figure 3.14A, panel b) is also 
another mechanism by which ADO could cause cell death. Previously, it was 





demonstrated that knockdown of EGFR by siRNA in human glioma cells has been 
shown to result in a decrease in cell survival (Kang et al., 2005). This is expected as 
EGFR is also a receptor that is known to be upstream of the mitogen associated 
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signalling cascades 
that control cell proliferation (Hynes & Lane, 2005), and thus downregulation of 
surface EGFR could inhibit tumour proliferation in the presence of growth factors.  
 
Currently, there are two main classes of anti-cancer agents targeting EGFR (Hynes & 
Lane, 2005; Zhang et al., 2007). The first class is made up of monoclonal antibodies 
such as cetuximab and panitumumab, which target the extracellular domain of EGFR 
to inhibit ligand binding. Reversible and irreversible tyrosine kinase inhibitors such as 
gefitinib and erlotinib form the second class, and they inhibit the activation of EGFR, 
and hence the downstream cell proliferation signalling pathways (Yap et al., 2009; 
Zahorowska et al., 2009). We have shown here for the first time that ADO, a small 
chemical compound which does not belong to these two classes of anti-cancer agents, 
can be used to target EGFR. Another emerging small molecule in the area of anti 
cancer therapy is the major catechin found in green tea (–)-epigallocatechin gallate 
(EGCG) (Yang et al., 2009a). EGCG has not only been found to inhibit activation of 
EGFR and its downstream signaling pathways (Shimizu et al., 2008), but it is also 
capable of  downregulating EGFR by inducing its internalisation (Adachi et al., 2008), 
However, in contrast to ADO, EGFR internalised upon EGCG treatment is recycled to 
the cell surface upon removal of EGCG. Hence, the ability of ADO to increase the 
internalisation of cell surface EGFR and accumulate them in the late endosomes is 
unique.  






ADO has been shown previously to be anti-cancer in nature, as it induces cell cycle 
arrest at the G2/M phase in HepG2 cells (Li et al., 2007), and at the G0/G1 phase in 
HL-60 leukemic cells (Cheung et al., 2005). It can also induce apoptosis in cancer 
cells in a caspase-3 (Zhao et al., 2008) and -8 dependent manner (Zhou et al., 2006) 
as well as inhibit NF-κB binding of DNA by forming a covalent bond with the 
reduced 62 cysteine of p50 (Xia et al., 2004; Hidalgo et al., 2005). The 
immunosuppressive property of ADO through its effect on NF-κB would be useful for 
its utilisation as an anti-cancer drug, especially as NF-κB has emerged in the recent 
years as a target for cancer therapy (Baud & Karin, 2009).  NF-κB activation has been 
implicated in cancers such as breast, colon, liver, prostate, cervical and acute 
lymphocytic leukaemia, and its prolonged activation results in increased cell survival 
and proliferation, tumour metastasis and angiogenesis, factors which are involved in 
cancer progression (Baud & Karin, 2009). Our work on EGFR and TfR here has 
added a new dimension to the utilisation of ADO as an anti-cancer drug, as well as 
provided an understanding into how ADO regulates receptor trafficking in the cell. 
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4. Andrographolide increases surface EGFR downregulation 
through activation of p38 MAPK 
 
4.1. Abstract 
We have shown that ADO is capable of downregulating surface EGFR by increasing 
the rate of endocytosis. As EGFR is an important initiator of cell signalling pathways, 
it is possible that the ADO effect on EGFR trafficking could also affect EGFR-
induced signalling pathways such as the mitogen activated protein kinase (MAPK) 
pathways. Our studies show that ADO is capable of upregulating the phosphorylation 
state of all three MAPKs – ERK 1/2, p38 MAPK and SAPK/JNK. In particular, the 
increased phosphorylation of p38 MAPK led to an increase in its activity, and 
phosphorylation of EGFR at the serine 1046/1047 residues. This phosphorylation is 
responsible for inducing the increase in EGFR internalisation. 
4.2. Introduction 
One of the many mechanisms of ADO which modulates its anti-inflammatory effect is 
the ability to reduce levels of surface receptors, specifically inhibiting upregulation of 
the surface receptors I-A
b
, CD40 and CD86 in lipopolysaccharide stimulated dendritic 
cells (Iruretagoyena et al., 2005). Previously, we also demonstrated that ADO 
downregulated surface epidermal growth factor receptor (EGFR) and caused the 
accumulation of endocytosed EGFR by affecting its degradation (Tan et al., 2010). As 
receptor trafficking and signaling activation are closely related events, we were 
interested to further understand the effect that ADO has on EGFR trafficking and its 
downstream signaling pathways. 
 





EGFR is a key receptor tyrosine kinase responsible for controlling signaling pathways 
that mediate cellular proliferation. Upon the binding of its ligand, epidermal growth 
factor (EGF), the receptors dimerize, autophosphorylate and activate several mitogen 
activated protein kinase pathways (MAPKs), which include the extracellular signal 
regulated kinase 1 and 2 (ERK 1/2), the p38 mitogen activated protein kinase (p38 
MAPK) and stress activated protein kinase/c-Jun N-terminal activated kinase 
(SAPK/JNK). Phosphorylated EGFR is then internalised largely via endocytosis and 
degraded in the late endosomes to downregulate the signalling. However, it is known 
that internalised EGFR continues signalling in the endosomes. Hence, we postulated 
that the accumulation of intracellular EGFR could possibly affect downstream MAPK 
signalling.  
 
4.2.1. MAPK Pathways  
There are three major families of MAPKs – ERK1/2, p38 MAPK and JNK. They are 
serine/threonine kinases, and are activated upon dual phosphorylation of the 
conserved threonine and tyrosine residues in the threonine-X-tyrosine (TXY) motif 
within the conserved activation loop by their upstream MAPKK and MAPKKKs. 
Protein scaffolds bring these proteins into close proximity so that phosphorylation can 
occur (Pimienta & Pascual, 2007). The MAPKs are important signalling proteins as 
they dissociate from the scaffold and translocate to the nucleus upon activation, then 
they phosphorylate transcription factors (TFs) which control genes responsible for 
proliferation (ERK1/2), cellular response to stress and apoptosis (p38 MAPK and 
JNK) (Table 4.1). Phosphorylation of TFs enhances their transcription activity 
(Turjanski et al., 2007). In turn, mitogen kinase phosphatases (MKPs) regulate 





MAPK activity by dephosphorylating the TXY motif after a certain period of 
activation (Pimienta & Pascual, 2007). Hence, if ADO affects the activation of any of 
these MAPKs, it could affect cell fate. 
 
MAPK Transcription factors phosphorylated 
ERK 1/2  Sap-1a, ELK-1, SMAD-1, SMAD-2,3, SMAD4, MAF-A, p53, c-
Myb, SP1, c-Myc, c-Fos 
p38 MAPK ATF-2, c-Fos, ELK-1, c-Jun, p53, p73, MEF 2A, C, STAT-4,  
JNK c-Jun, ATF-2, ELK-1, JunD, ELK-3, p53, c-Myc, HSF-1, 
NFAT4. 
Table 4.1 Transcription factors phosphorylated by different MAPKs. (Adapted from 
(Turjanski et al., 2007) 
 
Several studies have investigated the effect of ADO on MAPK pathways with various 
contradicting results due to different cell types, ligands and incubation times used. 
However, ADO treatment in cancer cells generated a consistent upregulation of 
MAPK signalling: For cancer cell lines the increase in phosphorylated MAPK were: 
ERK1/2, p38 MAPK and JNK in liver carcinoma Hep3B cells (Ji et al., 2007); JNK in 
the presence of glutathione synthesis inhibitor in Hep3B cells (Ji et al., 2011); JNK in 
HepG2 cells (Zhou et al., 2008) and ERK1/2 in colon carcinoma CT26 cells were 
found to be activated upon ADO treatment (Chao et al., 2010b).  
 
4.2.2. Crosstalk between MAPK signalling and receptor endocytosis 
Conventionally, receptors were thought to activate downstream signalling molecules 
such as the MAPKs, and receptor endocytosis was then initiated to traffic receptors 
for degradation to attenuate receptor-induced signalling. Thus, endocytosis was 





thought of mainly as a process to downregulate signalling. However, recent studies 
have led to a paradigm shift in how signalling and endocytosis interact; signalling 
molecules such as the MAPKs are now known to be important players in regulating 
the endocytic process. For instance, while p38 MAPK activates the stress response 
pathway, it is also known to phosphorylate EGFR on serines within the region of 
1002 – 1020, as well as 1046/1047, causing its internalisation from the cell surface 
(Frey et al., 2006; Zwang & Yarden, 2006; Sorkin & Goh, 2009). Conversely, 
proteins involved in trafficking such as the growth factor receptor-bound protein 2 
(Grb2), which is commonly known to induce internalisation of receptor tyrosine 
kinases such as EGFR, can also activate signalling cascades through the Ras proteins 
(Sorkin & von Zastrow, 2009). Thus, to obtain a more holistic picture of ADO 
regulation of receptor trafficking, there is a need to understand how ADO regulates 
MAPK signalling. Specifically, we sought to understand the underlying mechanism 
by which ADO regulates MAPK signalling and its corresponding effect on EGFR 
trafficking. We demonstrate that ADO is capable of upregulating phosphorylation of 
MAPKs, in particular extracellular regulated kinase (ERK) 1/2, p38 MAPK and c-Jun 
N terminal Kinase (JNK) in an EGF independent manner. The activation of p38 
MAPK induced phosphorylation of EGFR at serine residues 1046/1047, causing its 
internalisation from the cell surface, and inhibition of p38 MAPK activity restores 
levels of surface EGFR downregulated by ADO. 






4.3.1. Andrographolide upregulates the MAPK signalling pathways 
independently of EGF 
 
Downregulation of EGFR signalling is mediated by endocytosis and degradation of 
phosphorylated EGFR. As we previously showed that EGFR is internalised from the 
cell surface and accumulated intracellularly, we were interested to determine whether 
this accumulation affected the EGFR signalling pathways, particularly the major 
MAPK pathways which regulate cell proliferation and apoptosis. Cells were 
pretreated with ADO in serum-free media for 4 h prior to incubation with 100 nM 
EGF (to induce MAPK signalling) and lysis at various time points. Interestingly, 
ADO is able to upregulate phosphorylation of MAPKs ERK1/2, p38 MAPK and p46 
of SAPK/JNK (Figure 4.1 A – D, lanes 1 and 2) even in the absence of EGF. As 
anticipated, total phosphorylation of EGFR remained unchanged. Thus, ADO can 
induce EGF-independent MAPK signalling in A-431 cells.  
 
Next, we were interested to understand the manner in which ADO induces MAPK 
signalling. MAPK signalling is highly dynamic due to its induction by upstream 
MAPKKs as well as regulation by protein phosphatases, and hence, there is a short 
time frame during which the MAPKs will be activated. This activation typically 
decreases shortly after due to dephosphorylation by the MKPs. Thus, we investigated 
the timepoint at which ADO induced MAPK signalling by incubating ADO with A-
431 cells for varying timepoints in serum-free media. Cells were then lysed and the 
phosphorylation level of EGFR and the MAPKs analysed. As was expected, total 
EGFR phosphorylation was unchanged, whereas the phosphorylation of p38 MAPK 





and p46 of SAPK/JNK was upregulated upon ADO treatment with increasing 
incubation times beginning at 1 h, and p42 of ERK at 2 h (Figure 4.2A). The MAPK 
activation was sustained till the endpoint of 4 h. This phenomenon was not limited to 
A-431, but was similarly replicated in the human cervical carcinoma cell line Hela 
after 4 h treatment with ADO in serum-free media (Figure 4.2B) hence demonstrating 
that ADO induction of MAPK pathways is not cell line specific. 





Figure 4.1 Andrographolide up-regulates the MAPK signalling pathways independently of 
EGF.A-431 cells were starved overnight in serum-free media, pre-treated with DMSO or 100 µM ADO for 4 
hours in serum-free media, and then either activated with 100 nM EGF for varying timepoints (A); or treated 
with DMSO or 100 µM ADO for varying time-points, lysed (B) and used for western blot analysis. VC, vehicle 
control; ADO, andrographolide. Phosphorylation of EGFR and major MAPK signalling pathways was 
determined using anti-phosphorylated EGFR (BD Biosciences) and total EGFR (A), phospho-ERK1/2 and total 
ERK1/2 (B), phospho-JNK and total JNK (C), and phospho-p38 MAPK and total p38 MAPK (D) antibodies. 
Blots are representative of at least two independent experiments. 
 





  Figure 4.2 Andrographolide upregulates MAPK signalling pathways phosphorylation 
independently of EGF in A-431 (A) and Hela (B) cells. Cells were starved overnight in serum-
free media, pre-treated with DMSO or 100 µM ADO for varying timepoints in serum-free media, lysed 
and analysed by western blot. VC, vehicle control; ADO, andrographolide. Phosphorylation of EGFR 
and major MAPK signalling pathways were determined using the same antibodies as figure 1. Blots are 
representative of at least two independent experiments. 
 





4.3.2. JNK and p38 MAPK activity regulate ADO induced EGFR 
internalisation 
 
Although phosphorylation of MAPKs is usually closely associated with the 
upregulation of MAPK activity, we wanted to be certain that ADO does not only 
upregulate the levels of phosphorylated MAPKs, but also increases their activity. 
Hence, we used a p38 MAPK activity assay to check for ADO effect on p38 MAPK 
activity. Cells were pretreated with ADO for 4 h, lysed and phosphorylated p38 
MAPK was incubated with its downstream signalling target, recombinant ATF-2 
protein. Levels of ATF-2 phosphorylation were then analysed by western blot. As 
anticipated, p38 MAPK is activated upon ADO treatment (Figure 4.3A).   
 
As p38 MAPK is known to induce EGFR internalisation (Vergarajauregui et al., 2006; 
Zwang & Yarden, 2006) by inducing EGFR phosphorylation, we postulated that the 
p38 MAPK activation by ADO could be responsible for regulating EGFR 
downregulation from the cell surface. Hence, we investigated the effect of MAPK 
inhibitors (MAPKi) on EGFR internalisation from the cell surface. A-431 cells were 
incubated with anti-EGFR antibody on ice, and the antibody was allowed to 
internalise at 37 °C for 4 h either in the absence or presence of ADO and MAPKi 
which were added together. ADO caused the accumulation of EGFR at the 
perinuclear region, and this accumulation was reduced in the presence of p38 MAPKi 
and JNKi, but not ERKi (Figure 4.3B).  
 
We were then interested to determine if continued p38 MAPK activity was required 
for accumulation of EGFR. EGFR antibody was internalised in the presence of ADO 





for 3 h to allow for p38 MAPK activation, and p38 MAPKi was then added for an 
hour. Cells were then fixed and visualized. After 1 h of treatment, p38 MAPKi can 
still inhibit the accumulation of EGFR at the perinuclear region, indicating that 
continued phosphorylation of EGFR by p38 MAPK is important for the accumulation 
of EGFR (Figure 4.3C).  







Figure 4.3 Andrographolide enhances endocytosis of EGFR via activation of the p38 
MAPK. Cells were incubated with anti-EGFR 29.1 mAb on ice for 1 h, then pre-treated with either 
DMSO, MAPKi in the presence or absence of 100 µM ADO in media at 37° C for 4 h (B), or pre-treated 
with DMSO or 100 µM ADO in media for 3 h before p38 MAPKi was added for the last hour (C). VC, 
vehicle control; ADO, andrographolide; MAPKi, MAPK inhibitors; 50 ADO, 50 µM ADO; 100ADO, 
100 µM ADO, EGF, 100 ng/ml EGF. Images are representative of at least two independent experiments. 
Scale bars are representative of 10 µm. 
A. ADO induced p38 MAPK phosphorylation results in increase of p38 MAPK kinase activity. Cells 
were starved overnight in serum-free media, and treated with ADO for 4 h or 100ng/ml of EGF for 15 
minutes. Cells were then lysed and processed using the p38 MAPK kinase kit. Blots are representative of 
at least three independent experiments. 
B. Inhibition of EGFR endocytosis by p38 MAPKi and JNKi.  
C. Continual p38 MAPK kinase activity is required for EGFR accumulation.  
 
 





We then went on to confirm if ADO induces the phosphorylation of EGFR on serine 
1046/1047 in a p38 MAPK dependent manner. A-431 cells were pre-starved in 
serum-free media, treated with ADO for 4 h, lysed and analysed using western blot. 
As expected, the antibody specific for full-length phosphorylated EGFR showed no 
difference upon ADO treatment. However, the antibody specific only for EGFR 
phosphorylated on serine 1046/1047 showed increased phosphorylation at both 50 and 
100 µM ADO (Figure 4.4A). Addition of p38 MAPKi did not affect phosphorylation 
of p38 MAPK, but it inhibited ADO induced phosphorylation of EGFR on serine 
1046 (Figure 4.4B). JNKi, in contrast, inhibited phosphorylation of JNK, but did not 
seem to affect phosphorylation of EGFR on serine 1046 (Figure 4.4C). Similar results 
were obtained for Hela cells (data not shown). 
 
Addition of MAPKi could partially rescue ADO downregulation of cell surface 
receptors. Hela cells were used as it is easier to detect changes in EGFR surface levels 
as they express physiological levels of EGFR, as compared to A-431, which over-
expresses EGFR. Cells were treated with ADO in the presence of either p38 MAPKi 
or JNKi for 4 h and analysed by flow cytometry for surface EGFR. ADO decreased 
surface EGFR by 25%, and addition of both p38 MAPKi and JNKi restored surface 
EGFR levels to approximately 95% after ADO treatment (Figure 4.5).  






Figure 4.4 Activated p38 MAPK phosphorylates EGFR in A-431 cells. A-431 cells were starved 
overnight in serum-free media, pre-treated with DMSO or 100 µM ADO for 4 hours in serum-free media in 
the presence or absence of 10 µM MAPKi. VC, vehicle control; ADO, andrographolide; MAPKi, MAPK 
inhibitors, pEGFR, phosphorylated EGFR; 50 ADO, 50 µM ADO; 100 ADO, 100 µM ADO. Phosphorylation 
of EGFR and major MAPK signalling pathways were determined using the same antibodies as figure 1 with 
the exception of pEGFR serine 1046/1047. Blots are representative of at least two independent experiments. 
A. ADO causes phosphorylation of EGFR at serine 1046/1047 in A-431 cells. 
B. p38 MAPKi inhibits ADO phosphorylation of EGFR at serine 1046/1047 in A-431 cells. 
C. JNKi does not inhibit ADO phosphorylation of EGFR at serine 1046/1047 in A-431 cells. 


















Activation of signalling pathways is a typical down-stream effect of ligand-receptor 
interaction, especially for growth receptors such as EGFR. The activated receptors are 
endocytosed and trafficked to the late endosome as a mechanism to downregulate 
signalling. However, in recent years, new evidence that proteins involved in signalling 
pathways can conversely regulate receptor trafficking and endocytosis has been 
emerging (Sorkin & von Zastrow, 2009). Earlier studies on p38 MAPK showed that it 
phosphorylates EGFR on threonine 669 (Winograd-Katz & Levitzki, 2006), residues 
1002 – 1020 (Zwang & Yarden, 2006) and serine 1046/1047 (Adachi et al., 2009a), 
and these residues are involved in the internalisation of EGFR. However, the exact 
mechanism of how phosphorylation of these residues induce EGFR endocytosis is not 
yet known (Sorkin & Goh, 2009). In a recent study, both p38 MAPK and EGF 
induced EGFR endocytosis was shown to be clathrin dependent, but p38 MAPK 
Figure 4.5 Andrographolide induced p38 MAPK phosphorylates EGFR, causing 
downregulation of surface EGFR in Hela cells. Hela cells were starved overnight in serum-free 
media, pre-treated with DMSO or 100 µM ADO for 4 hours in serum-free media in the presence or 
absence of 10 µM MAPKi. VC, vehicle control; ADO, andrographolide; MAPKi, MAPK inhibitors, 
pEGFR, phosphorylated EGFR. Phosphorylation of EGFR and major MAPK signalling pathways were 
determined using the same antibodies as figure 1 with the exception of pEGFR serine 1046/1047. Blots 
are representative of at least two independent experiments. 














mediated EGFR endocytosis was shown to require the di-leucine and YRAL motif to 
interact with adaptor protein-2 (AP-2) complex; whereas EGF induced EGFR 
endocytosis was Grb2 dependent (Grandal et al., 2011). The di-leucine motif exists at 
residues 1010 – 1011, and hence it corresponds with the region of 1002 – 1020 as 
reported by Zwang et al. earlier on. 
 
p38 MAPK activation is also known to increase endocytosis rates via enhancing the 
formation of the cytosolic guanyl-nucleotide dissociation inhibitor (GDI):Rab5 
complex. GDI is responsible for sequestering Rab5 in the cytosol, away from 
membranes where it mediates endosomal fusion. GDI:Rab5 can either be directly 
involved in endosome formation, or it can increase recruitment of the Rab5 GTPase, 
to regions where endosomal formation is occurring (Cavalli et al., 2001; Clague & 
Urbe, 2001). The α isoform of p38 MAPK can also increase endocytosis by 
phosphorylating the Rab 5 effectors EEA-1 on threonine 1392 and Rabenosyn-5 on 
serine 215 within their FYVE domain, which is responsible for binding to the 
phosphatidylinositol-3 phosphate (PI(3)P) in endosomes, to induce increased 
membrane recruitment (Mace et al., 2005). It would be interesting to uncover the 
mechanism through which ADO activates p38 MAPK for future studies. 
 Previous work on ADO has demonstrated that ADO upregulates the production of 
reactive oxygen species, hence leading to an increase in phosphorylation of the p46 
and p54 subunit of JNK, and this increase was blocked by adding the antioxidant N-
acetyl cysteine (Zhou et al., 2008). We were interested to determine whether the 
ADO-induced phosphorylation of ERK1/2, p38 MAPK and JNK could be blocked by 
the addition of L-cysteine, and hence we pre-incubated ADO with 5mM of L-cysteine 





for an hour before adding the resulting mixture to the cell culture. We chose L-
cysteine to eliminate the possibility of the acetyl group playing any role in the 
reaction. L-cysteine is also capable of scavenging reactive oxygen species. In the 
presence of L-cysteine, ADO was no longer able to induce ERK1/2, p38 MAPK and 
JNK phosphorylation (Figure 4.6).  
  
Figure 4.6 L-cysteine inhibits MAPK induced signalling. L-cysteine is capable of blocking the effect 
of ADO on MAPK signalling pathways. 100µM ADO was pre-incubated with L-cysteine for 1 h, then added 
to A-431 cells for 4 h and lysed for western blot analysis. VC, vehicle control; ADO, andrographolide; 
MAPKi, MAPK inhibitors. Phosphorylation of EGFR and major MAPK signalling pathways were determined 
using the same antibodies as Figure 4.1. 
 





ADO is known to induce JNK activation via upregulation of free cellular glutathione, 
and chemical inhibition of free glutathione synthesis prevents ADO induced JNK 
activation (Ji et al., 2011).  Previously, ADO has also been shown to increase levels 
of hydrogen peroxide in HepG2 human hepatoma cells (Li et al., 2007). This 
accumulation of hydrogen peroxide is most likely due to the increased activity of 
superoxide dismutase (SOD), hence reducing the overall levels of superoxide and 
increased levels of hydrogen peroxide. Although hydrogen peroxide can be 
decomposed by catalase (CAT) to give water and oxygen (Figure 4.7), and ADO 
upregulates CAT activity, hydrogen peroxide can be accumulated if its rate of 
production is higher than its rate of removal. 
 
Hydrogen peroxide is known to activate the MAP3K molecule apoptosis signal-
regulating kinase-1 (ASK-1), which is inhibited by complexing to thioredoxin [TrxR-
(SH)2] (Saitoh et al., 1998). In the presence of oxidative stress, the thiol group of 
thioredoxin is oxidised to form thioredoxin disulphide (TrxR-S2) and dissociates from 
ASK-1 (Yoshioka et al., 2006), leading to recruitment of TNF receptor associated 
factor 2 and 6, resulting in phosphorylation of threonine 838 in the activation loop of 
human ASK-1 (Matsuzawa & Ichijo, 2008), allowing it to phosphorylate the 
downstream MAP2Ks, and eventually lead to JNK and p38 activation. ASK-1 is 
negatively regulated by phosphorylated Akt, which phosphorylates it at the serine 83 
residue. As ADO induced JNK and p38 MAPK signalling is eliminated in the 
presence of the anti-oxidant L-cysteine, we speculate here that a possible mechanism 
of p38 MAPK activation could be through the ADO-induced increase in intracellular 
hydrogen peroxide levels, leading to activation of ASK-1, and downstream JNK and 





p38 MAPK. The resultant active p38 MAPk then phosphorylates EGFR at serine 
1046/1047 and induces its internalisation (Figure 4.8).  
Figure 4.7 Production and removal of reactive oxygen species (ROS) (Comhair 
& Erzurum, 2010). Superoxide is removed by superoxide dismutase (SOD) to give 
hydrogen peroxide. Catalase then causes decomposition of hydrogen peroxide to give water 
and oxygen. Permission granted courtesy of Mary Ann Liebert. 
 
A 





Figure 4.8 Proposed model of ADO effect on p38 MAPK signalling and EGFR endocytosis. 
In the absence of ADO, thioredoxin is in its reduced form, and acts to inhibit ASK-1, thus there is no 
activation of p38 MAPK. However, in the presence of ADO, hydrogen peroxide levels are up-regulated 
and this leads to the oxidation of thioredoxin. Thioredoxin dissociates from ASK-1 and this leads to its 
activation, causing MKK3/6 and p38 MAPK to be phosphorylated. p38 MAPK then moves to 
phosphorylate EGFR on serine 1046/1047, thus causing it to endocytose, reducing overall surface levels of 
EGFR. ADO elevation of hydrogen peroxide levels is inhibited in the presence of the anti-oxidant L-
cysteine. 
 





Conversely, phosphorylation of ERK1/2 is well known to activate cellular 
proliferation pathways and to inhibit apoptosis. However, it has been demonstrated 
that oxidative stress induced by hydrogen peroxide can lead to activation of ERK1/2 
through activation of the Src kinase, or in a Ras-dependent or independent manner. 
Interestingly, ERK1/2 activation in some cases has been shown to be capable of 
inducing apoptosis in cells  (McCubrey et al., 2006). 
 
The activation of the p38 MAPK, JNK and ERK1/2 may contribute to the reduction in 
cell survival upon ADO treatment, as they could induce apoptosis. Inhibition of p38 
MAPK and JNK activation led to slight increases in cell viability, but inhibition of 
ERK1/2 did not induce significant change (Figure 4.9). 
 
In summary, we have shown here that ADO downregulation of surface EGFR is due 
to its activation of p38 MAPK. ADO is not the only natural compound known to 
activate p38 MAPK and induce downregulation of surface EGFR. Other compounds 
such as epigallocatechin-3-gallate (EGCG) (Adachi et al., 2009b), the active 
compound extracted from green tea, have been shown to induce p38 MAPK 
activation and cause EGFR phosphorylation at serine 1046/1047, causing 
downregulation of surface EGFR and inhibiting cell proliferation (Adachi et al., 
2008). This thus indicates the plausible use of dietary supplements to exert anti-
carcinogenic effects to decrease surface levels of EGFR, and this could be an 
approach that is used in combination with current chemotherapy to reduce expression 
of EGFR in cancer cells. 








Figure 4.9 MAPKi can partially restore cell viability in A-431 cells. A-431 cells were treated 
for 24 h with varying concentrations of ADO in the presence or absence of MAPK inhibitors (MAPKi) 
and the amount of viable cells quantitated by the MTT assay. *,  p < 0.05.  
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5. Andrographolide regulates phagocytosis in microglia cells 
through downregulation of CD204 
5.1. Abstract 
It has been demonstrated in our earlier studies that ADO is capable of downregulating 
surface EGFR through phosphorylating EGFR on serine 1046/1047 residues. ADO is 
also known to inhibit dendritic cell maturation through suppressing important 
receptors such as CD40, CD80 and CD86. We postulated that one of the anti-
inflammatory mechanisms of ADO could be due to its ability to decrease surface 
receptors of immune cells, hence we investigated the effect of ADO on surface 
scavenger receptor trafficking in N9 microglia cells. We found that ADO is capable of 
inhibiting phagocytosis by up to 50% through decreasing surface CD204, and this was 
mediated by inhibiting trafficking of CD204 to the cell surface. 
 
5.2. Introduction 
Bacterial meningitis is the inflammation of the meninges, typically caused by 
Streptococcus pneumonia, Neisseria meningitidis and in some cases, Mycobacterium 
tuberculosis. It occurs due to microbial penetration of the blood brain barrier (BBB) 
via interaction with receptors on the host endothelium (Kim, 2003). A lack of an 
immune response in this immunoprivileged area allows the microbes to rapidly 
multiply, resulting in the colonisation of the subarachnoid cavity. Bacteria in the 
cavity can then autolyse to release components such as pneumolysin, 
lipopolysaccharide, lipotechoic acid and bacterial DNA which then activate microglia, 
meningeal and perivascular macrophages through the toll like receptors. Pro-
inflammatory cytokines such as TNF-α and IL-1β are then released, increasing BBB 






permeability and causing the recruitment of leukocytes. Breakdown of the BBB then 
ensues, leading to brain edema and increased intracranial pressure. Inflammation of 
the CNS also results in the release of reactive oxygen species which causes neuronal 
injury and cell death (Gerber & Nau, 2010). Hence, 15 % of meningitis cases 
experience neurological sequelae in the form of seizures, loss of hearing as well as 
learning deficits (Saez-Llorens & McCracken, 2003).  
 
ADO is a known anti-inflammatory agent which can also modulate 
neuroinflammation. It is capable of ameliorating the progression of EAE through 
inhibiting activation of dendritic cells, thereby downregulating the expression of 
MHC class II molecules on the cell surface, hence decreasing antigen presentation to 
T cells. T cells in turn proliferate to a smaller extent resulting in a decrease in IFN-γ 
and IL-2 production (Iruretagoyena et al., 2006). Microglia activation by 
lipopolysaccharide (LPS) and the resultant release of proinflammatory factors was 
also specifically suppressed by ADO treatment (Wang et al., 2004). Activation of 
OX-42 positive microglia and production of inflammatory markers in a rat model of 
cerebral ischaemia was similarly inhibited upon ADO treatment (Chan et al., 2010). 
  
ADO has been convincingly demonstrated to be an anti-inflammatory compound 
through its effects on the NF-κB signalling pathway – preventing binding of the p50 
subunit of NF-κB to its target sequence (Xia et al., 2004), as well as inhibiting 
phosphorylation of the upstream IκB kinase (IKK) complex, thus preventing 
downstream nuclear translocation of the p65 subunit of NF-κB (Bao et al., 2009). 






However, the possibility of a separate mechanism for the anti-inflammatory action of 
ADO still exists, as drugs are known to act on a variety of pathways. Interestingly, 
ADO was able to downregulate receptors from the cell surface such as CD40, CD80 
and CD86 in dendritic cells (Iruretagoyena et al., 2005), as well as the epidermal 
growth factor receptor (EGFR) in A-431 epidermoid carcinoma cells (Tan et al., 2010) 
through phosphorylation of EGFR on the serine 1046/1047 residues. Although it does 
not decrease surface EGFR via affecting general cellular endocytosis mechanisms, it 
is possible that it could also lead to the lowered surface expression of other surface 
receptors. As scavenger receptors are important for the phagocytic uptake of antigens 
in antigen presenting cells (Husemann et al., 2002), it is possible that ADO could 
inhibit inflammation by downregulating surface expression of scavenger receptors, 
hence affecting phagocytosis.  
 
5.2.1. Scavenger Receptors 
Scavenger receptors (SRs) are an important class of receptors expressed on 
phagocytic cells which are responsible for the uptake and removal of a variety of 
foreign substances, such as cell debris and bacteria. They also play key roles in 
modulating lipid metabolism through the uptake of lipoproteins, and different 
scavenger receptors endocytose different forms of lipoproteins, which may be native 
or modified (acetylated or oxidized) (Ashraf & Gupta, 2011). SRs are divided into 8 
classes (A – H) based on their different structural domains.  
 






Class A scavenger receptors contain a common collagenous domain, and its members, 
which include the three isoforms of scavenger receptor A (SR-AI, II and III) and 
macrophage receptor with collagenous structure (MARCO) have a common cysteine 
rich region (Pluddemann et al., 2007). SR-A binds to the lipopolysaccharide (LPS) 
found on the cell walls of bacteria (Doi et al., 1993; Nakamura et al., 2001), as well as 
other bacterial ligands on Neisseria meningitidis, and SR-A knock-out mice have 
higher rates of infection due to an inability to clear bacteria (Pluddemann et al., 2006). 
Recombinant soluble MARCO consisting of the spacer, collagenous and cysteine rich 
domains similarly binds to LPS (Sankala et al., 2002), and has been shown to bind to 
Clostridium sordellii (Thelen et al., 2010) and Neisseria meningitidis (Mukhopadhyay 
et al., 2006; Pluddemann et al., 2009). 
 
CD36 belongs to the SR class B family, and it contains loops with multiple 
glycosylation sites. It is known to bind to the lipoteichoic acid of Staphylococcus 
aureus (Stuart et al., 2005), and has also been shown to be involved in the uptake of 
various bacteria such as E. coli K12 and K25, Enterococcus faecalis, Klebsiella 
pneumoniae, Salmonella typhimiurium (Baranova et al., 2008). Presence of CD36 is 
important for Mycobacterium tuberculosis infection of the host (Hawkes et al., 2010). 
 
We investigated the effect of ADO on phagocytic uptake of antigens by microglial 
cells. Microglia are resident macrophages of the brain (Muzio et al., 2007), and are 
thought to be involved in the initiation of inflammation via their pattern recognition 
receptors. They are also capable of phagocytosing foreign materials and displaying 






peptides on MHC class II for T cell activation. Here, we demonstrate that ADO is 
able to inhibit phagocytosis in microglial cells by downregulating cell surface 
expression of scavenger receptor CD204 and CD36. Our results suggest that ADO 
could alleviate inflammatory responses due to its ability in downregulating receptors 
that mediate non-opsonic phagocytic uptake of antigens and presentation by 
microglial cells. 
 






5.3. Results   
5.3.1. Andrographolide regulates phagocytosis in microglial cells 
ADO is well known for suppressing immune responses via inhibiting NF-κB 
activation, but we were interested to see if ADO could affect the immune response at 
another level. We postulated that ADO downregulation of surface scavenger receptors 
would affect phagocytic uptake of particulate antigens, and we investigated 
phagocytosis using fixed bacteria as an antigen. Bacteria were chosen as they express 
physiological ligands for scavenger receptors, and fixed bacteria were used to prevent 
bacteria growth and induction of microglia cell death. 
 
Cells were treated with ADO for 3 hours, and allowed to phagocytose green 
fluorescent protein (GFP) E. coli bacteria for 10 minutes in the presence of the drug 
and fixed. The amount of phagocytosed bacteria was then quantified by flow 
cytometry. Interestingly, the inhibition in phagocytosis is dose-dependent (Figure 
5.1A), and phagocytosis is inhibited up to 50% for 50 M of ADO. To visually 
confirm that phagocytosis was indeed down-regulated, microglia cells were allowed 
to phagocytose bacteria for 20 minutes before they were washed and fixed. 
Immunofluorescence was performed to check for the number of bacteria bound per 
cell with drug treatment. The number of bacteria binding to 200 cells for each 
concentration were then counted, and triplicates were performed for each 
concentration. Phagocytosis rates decreased by up to 50% at 50 M of ADO as shown 
in Figure 5.1B. Cell viability on the other hand, was unaffected upon treatment with 
ADO up to 120M for 3 hours (data not shown). ADO is known to inhibit NF-κB 
activation, which is activated by lipopolysaccharide (LPS) through Toll like receptor 






4 (Xia et al., 2004). As LPS is known to induce an increase in phagocytosis in 
microglia and macrophages (Wu et al., 2009; Sivagnanam et al., 2010), there is a 
possibility that perturbing the LPS signalling pathway may in turn affect phagocytosis. 
In order to rule out the possibility that ADO affected phagocytosis rates through 
inhibiting the NF-κB pathway, we allowed N9 to phagocytose latex beads. 
Phagocytosis was similarly down-regulated up to 50% (Figure 5.1C), indicating that 
the ADO effect on phagocytosis was not dependent on the presence of LPS.  







Figure 5.1 ADO down-regulates phagocytosis in microglia. 
A. Effect of ADO treatment on phagocytosis. N9 cells were treated for 3 hours with varying 
concentrations of andrographolide, incubated with fixed GFP expressing bacteria for 10 
minutes, then fixed and analysed by flow cytometry. ***, P < 0.005 relative to vehicle 
control; Graph is representative of at least 3 independent experiments.  
B. Visualisation of bacteria binding to microglia after andrographolide treatment.  
a. N9 cells were treated for 3 hours with varying concentrations of ADO, incubated with fixed 
GFP bacteria for 20 minutes and fixed. Triplicates of each concentration were used, and the 
number of bacteria binding to 200 cells was counted for each coverslip. Graph is 
representative of at least 2 independent experiments. 
b. Immunofluorescence photos of bacteria binding to N9 cells after 20 minutes. Pictures are 
representative of at least 2 independent experiments. Scale bars are representative of 10 μm. 
C. Effect of andrographolide treatment on phagocytosis of latex beads. N9 cells were treated for 
2 hours with varying concentrations of ADO, incubated with 1m polystyrene beads for 1 
hour, then fixed and analysed by flow cytometry. **,P < 0.001 relative to vehicle control; 
Graph is representative of at least 3 independent experiments.  VC, vehicle control; ADO, 
andrographolide; GFP, green fluorescent protein. 
 






5.3.2. Andrographolide decreases the surface expression of CD204 and 
CD36 
 
Phagocytosis of bacteria is known to be mediated by scavenger receptors. As we have 
previously demonstrated that ADO is capable of downregulating expression of 
epidermal growth factor receptors (EGFR) on the surface of A-431 cells (Tan et al., 
2010), it was highly likely that andrographolide could have also down-regulated cell 
surface expression of scavenger receptors in N9 cells. To elucidate this drop in 
phagocytic activity, the surface expression of three scavenger receptors: class A 
scavenger receptors CD204, otherwise known as scavenger receptor A (SR-A), and 
MARCO (data not shown), as well as CD36, a class B scavenger receptor, were 
studied following drug treatment for 3 h. Interestingly, surface levels of CD36 and 
CD204 were reduced by about 20% upon 50µM ADO treatment (Figure 5.2A). 
However, the total receptor levels remained unchanged as shown by western blot 
(Figure 5.2B). 
















Figure 5.2 ADO induces a decrease in surface expression of CD204 and CD36. 
A. ADO downregulates cell surface receptor levels. N9 cells were treated for 3 hours with varying 
concentrations of ADO and stained with antibody against CD36 and CD204. Flow cytometry 
results are representative of at least 3 independent experiments. *, P < 0.05 relative to vehicle 
control; **, P < 0.01 relative to vehicle control. 
B. ADO does not affect total levels of receptors. N9 cells were treated for 3 hours with varying 
concentrations of ADO and lysed. CD36 and CD204 levels were analysed by non-reducing 










5.3.3. CD204 is important for phagocytosis of E. coli in N9 microglia cells 
Different SRs have varying domains that bind to different bacteria. As the SRs tested 
were down-regulated from the cell surface, we were interested to find out which 
receptors were responsible for the downregulation of phagocytosis of E. coli in N9. 
Hence, we blocked the receptors using inhibitory antibodies of varying concentrations 
for CD36, CD204 and MARCO, and assayed for phagocytosis levels using the 
Vybrant phagocytosis assay. Interestingly, only the CD204-specific antibody caused a 
significant drop of more than 50% in phagocytosis, indicating that it is the main 
scavenger receptor responsible for phagocytosis in N9 (Figure 5.3B). The drop in 
phagocytosis was the same for 5µg/ml and 20 µg/ml of antibody, showing that the 
capability of anti-CD204 antibody in blocking bacteria binding and phagocytosis was 
saturated at 5µg/ml.  
 
  







Figure 5.3 CD204 is important for phagocytosis in N9 microglia cells. N9 cells were incubated on 
ice with varying concentrations of antibody for an hour, and then incubated with fluorescent bioparticles from 
the Vybrant Phagocytosis Assay for an hour at 37 °C. The amount of bioparticles phagocytosed was then 
analysed by the fluorescent reader. Graphs are representative of at least 2 independent experiments. VC, 
vehicle control. 
A. Anti-CD36 does not block phagocytosis in N9 microglia cells. 
B. Anti-CD204 blocks phagocytosis in N9 microglia cells. **, P <0.01 relative to vehicle control. 
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5.3.4. CD204 accumulates within the cell upon ADO treatment  
Since CD204 was important for N9 phagocytosis, and surface CD204 is 
downregulated upon ADO treatment, we were interested to identify the pathway of 
CD204 trafficking affected upon treatment. Hence, we observed the distribution of 
CD204 in N9 using immunofluorescence. Cells were treated with ADO for 3 h, fixed, 
permeabilized and stained for CD204. Intracellular endosomal structures containing 
CD204 seemed to be much larger upon ADO treatment, particularly for 50 µM 
(Figure 5.4A). The cellular compartment which CD204 localises to specifically was 
then determined by co-localization study using different endosomal markers. 
Interestingly, CD204 partially co-localises with early endosomal antigen-1 (EEA-1), a 
marker of early endosomes, as well as VAMP-3, a marker of recycling endosomes, in 
both untreated (VC) and ADO treated cells upon confocal microscopy analysis 
(Figure 5.4B-D). Hence, it is likely that surface CD204 has been downregulated from 
the cell surface and accumulated within the early and recycling endosomes.  













Figure 5.4 ADO causes an accumulation of CD204 in intracellular endosomal compartments. 
Images were taken using the Leica TCS SP5 confocal microscope, and are representative of at least 2 independent 
experiments. N9 cells were treated for 3 hours with varying concentrations of ADO and stained with anti-CD204 
antibody (A) or together with an appropriate co-localizing antibody (B-D). Scale bars are representative of 10 µm. 
VC, vehicle control, ADO, andrographolide. 
A. CD204 accumulates within the cell upon andrographolide treatment. Arrows indicate the increased 
accumulation of CD204. 
B. CD204 co-localises with the early endosomal marker, EEA-1. Arrows indicate the increased 
accumulation of CD204. 
C. CD204 co-localises with the recycling endosomal marker, VAMP-3. 
D. Confocal analysis of CD204 co-localization with EEA-1 and VAMP-3, using X-Z/Y-Z projection of 
CD204 co-localization with EEA-1 or VAMP-3. X-Z/Y-Z projection was performed using the Leica LAS 











5.3.5. ADO does not inhibit endocytosis or degradation of CD204 
As CD204 seems to accumulate within the cell, it was possible that the endocytosis or 
degradation rates of CD204 were changed upon treatment. We first investigated if 
there was any change in endocytosis rates of CD204 by immunofluorescence. CD204 
antibody was allowed to bind to N9 on ice, and then endocytosed and fixed at 
different time points. Cells were then probed using EEA-1 as a marker for the early 
endosomes. Co-localisation of CD204 with EEA-1 was utilized to measure 
internalization of surface CD204 into the early endosomes. Interestingly, there did not 
seem to be any increase in the rate of endocytosis upon ADO treatment as is evident 
from the images (Figure 5.5A). We quantified the average amount of co-localisation 
using the Pearson’s Correlation of five unique frames for each sample, at each 
specific time-point, and there is no significant difference between VC and ADO 
treated cells.  
 
To ensure that the results from the immunofluorescence studies were reliable, levels 
of endocytosed CD204 in DMSO and ADO treated cells were also quantified by flow 
cytometry. FITC-conjugated CD204 was allowed to bind to N9 on ice and CD204-
specific antibody was allowed to endocytose at 37 °C for different time points. 
CD204 remaining on the cell surface was then removed with acid wash, and cells 
were fixed. Similarly, there was no significant difference between VC and ADO 
treated cells (Figure 5.5 B).  
 






Hence, we went on to investigate whether the increased accumulation of intracellular 
CD204 could be due to the ADO effect on degradation rate of CD204. N9 cells were 
pretreated with ADO, CD204 antibody was allowed to bind to the cell surface of N9 
on ice, and then allowed to endocytose at 37 °C. The amount of remaining CD204 at 
various times was then quantified by western blot. However, the degradation of 
CD204 within the cell does not seem to be inhibited by ADO (Figure 5.5 C).  












Figure 5.5 ADO does not alter the rate of CD204 endocytosis or degradation.   
A. Images were taken using the Leica TCS SP5 confocal microscope, and are representative of at least 2 
independent experiments. Cells were pre-treated with DMSO or 100M ADO for an hour, before 
incubation with anti-CD204 on ice. Cells were then replaced in 37 C, allowed to internalise and fixed at 
various timepoints. The numbers at the top right-hand corner represent the Pearson’s correlation for EEA-
1 and CD204, and are averages of correlations taken from at least 7 images. Images are representative of 
at least 2 independent experiments. Scale bars are representative of 10 µm. Arrows indicate co-
localization of CD204 and EEA-1. 
B. CD204 endocytosis rates were quantified. Cells were pre-treated with DMSO or 50M ADO for 3 h, 
before incubation with anti-CD204 on ice. Cells were then replaced in 37 C and allowed to internalise, 
excess antibody on the surface was washed off with acid and fixed at various timepoints and endocytosed 
CD204 was analysed by flow cytometry.  
C. CD204 degradation rates are not affected upon ADO treatment. Cells were pretreated with DMSO or 50 
M ADO for 2 h, before incubation with anti-CD204 on ice. Cells were then replaced in 37 C and lysed 
at various timepoints and analysed by western blot. Western blots are representative of at least 2 











Since both the endocytosis and degradation of CD204 was not affected by ADO, it 
appears that ADO effect on CD204 is different as compared to its effect on EGFR, 
and there could be a unique mechanism by which it decreases surface CD204. As 
CD204 containing endosomal structures were enlarged upon ADO treatment, we 
postulated that this phenomenon could result from ADO affecting secretion rates of 
CD204. CD204 is known to act as an adhesion molecule and is important in the 
formation of focal adhesion complexes (Post et al., 2002). During our experiments, 
we have consistently observed the detachment of microglia cells from the tissue 
culture surfaces during treatment, indicating that CD204 secretion could be affected. 
In immunofluorescence studies, we also observed that CD204 could be secreted on 
the surface of the cover-slip, leaving a cellular “footprint”, and these “footprints” 
were reduced in the presence of ADO. These various lines of evidence led us to 
investigate if CD204 secretion was affected in the presence of ADO. Cells were 
treated with ADO for 8 hours, detached, and the amount of CD204 secreted was 
quantified. Levels of CD204 that were secreted dropped drastically up to 70% after 8 
h of treatment (Figure 5.6A).  
 
Since secretion of CD204 was affected, it was possible that this could have been due 
to ADO effect on cellular secretion mechanisms. The vesicle-associated membrane 
protein (VAMP)-8 is well-known to be responsible for controlling granular secretion 
in platelets (Polgar et al., 2002), and it localises to secretory vesicles and controls 
degranulation (Jones et al., 2012). Thus, we investigated if VAMP-8 co-localised to 
the enlarged CD204 endosomes. Cells were treated for 8 h, before they were fixed and 
stained for CD204 and VAMP-8 and visualized with the confocal microscope (Figure 






5.6 B,C). As can be seen from the confocal images and the X-Z/Y-Z projections, 
CD204 and VAMP-8 do co-localise. Hence, it is possible that ADO could affect 
CD204 secretion via affecting VAMP-8 expression or function.  














Figure 5.6 Andrographolide affects the secretion of CD204  
A. Secretion of CD204 was decreased upon ADO treatment. Cells were pre-treated with DMSO and varying 
concentrations of ADO for 8 h, before cells were detached and the secreted CD204 on the plate was fixed. 
Anti-CD204 antibody and the corresponding fluorescence conjugated secondary antibody was added and 
the levels of fluorescence detected by a fluorescent reader. Amount of CD204 secreted is expressed as a 
percentage of the vehicle control. Graph is representative of at least 2 independent experiments. *, p < 
0.05. VC, vehicle control.  
B. ADO-induced accumulated CD204 is trapped in VAMP-8 positive endosomal structures. Cells were pre-
treated with DMSO and varying concentrations of ADO for 3 h, before cells were fixed and stained with 
anti-CD204 and anti-VAMP-8 antibody, followed by the fluorescence conjugated secondary antibody. 
Cells were visualized with the Leica TS5 confocal microscope. VC, vehicle control; ADO, 
andrographolide. Scale bars are representative of 10 µm. 
C. X-Z/Y-Z projection of CD204 co-localization with VAMP-8. Images were taken using the Leica TS5 
confocal microscope. X-Z/Y-Z projection was performed using the LAS AF Lite software. Scale bars are 
representative of 10 µm. 






5.4. Discussion  
Phagocytosis is the process by which antigen presenting cells (APCs) take up antigens 
present in the extracellular environment for processing before they are presented to 
the T cells. During phagocytosis, surface scavenger receptors such as CD204 bind to a 
bacterial ligand, which is then internalised by the APC to form phagosomes. The 
phagosome then undergoes maturation as different proteins are acquired and the 
phagosome becomes more acidic due to fusion with the lysosomes. This acidic 
environment activates the lysosomal cathepsins to degrade the antigens and peptides 
are produced, which are then complexed with MHC class II molecules. The antigen-
bound MHC class II molecules would then be presented on the cell surface and serve 
as activators of T cells (Kinchen et al., 2008). During ADO treatment, surface CD204 
is decreased, leading to decreased bacteria binding and phagocytosis. Fewer peptides 
are hence present within lysosomes for loading onto MHC class II molecules. 
Subsequently, fewer antigen-bound MHC class II molecules are presented on the cell 
surface, resulting in a decreased activation of T cells, less immunostimulatory 
molecules like cytokines being released and reduced inflammation. ADO is known to 
be an immunosuppressive compound via suppressing activation of NF-κB (Xia et al., 
2004), as well as inhibiting T cell activation through decreasing antigen presentation 
(Iruretagoyena et al., 2005). Thus, it has been shown to alleviate disease in many pre-
clinical models of inflammation such as experimental autoimmune encephalomyelitis 
(EAE) (Figure 1.1). Here, we demonstrate a novel mechanism through which ADO 
may have immunosuppressive effects – through downregulating scavenger receptors 
to reduce phagocytosis, hence affecting antigen presentation.  
 






From our experiments, ADO does not affect surface expression of CD204 through the 
endocytic pathway or the degradation pathway, but by inhibiting its trafficking to the 
cell surface via the secretory pathway. ADO could possibly affect VAMP-8 function 
or expression, hence affecting the secretion of CD204 as it is co-localised with 
enlarged CD204 endosomal structures.  
 
The ligand-independent endocytic pathway of CD204 is not fully characterised, 
although acetyl-low density lipoprotein (Ac-LDL) induced endocytosis has been 
investigated. Ac-LDL induced CD204 endocytosis is known to proceed via clathrin 
coated pits (Chen et al., 2006), although a recent study found that fucoidan induced 
CD204 endocytosis via caveolae (Zhu et al., 2011). SR-A is made up of three 
subtypes which form due to alternative splicing. SR-A I is the longest subtype, and 
exists as a trimer with six domains, of which the cytoplasmic domain has been shown 
to be important in regulating Ac-LDL endocytosis (Daugherty, 2000) (Figure 5.7). 
Phosphorylation of CD204 is important for controlling its endocytosis, as treatment 
with the protein kinase C inhibitor staurosporine inhibits Ac-LDL internalisation 
(Fong, 1996). However, phosphorylation can either enhance or inhibit internalisation, 
as inhibiting phosphorylation of the conserved residues serine 21 (serine 21 in the 
mouse, serine 20 in the human) increased internalisation, whereas inhibiting 
phosphorylated serine 49 (serine 49 in the mouse, serine 48 in the human) decreased 
internalisation (Fong & Le, 1999). Deletion studies which removed the first 49 amino 
acids (Kosswig et al., 2003) as well as the first 27 amino acids (Chen et al., 2006) of 
the cytoplasmic domain led to the reduced internalisation of Ac-LDL. The VXFD 
motif (residues 21-24 in human SR-A) as well as the di-leucine motif (which is 






known to play a key role in the internalisation of other receptors) in the cytoplasmic 
domain were important for receptor internalisation (Morimoto et al., 1999; Chen et al., 
2006), although the di-leucine motif was not responsible for binding to clathrin. Both 
deletion of the first 27 amino acids and mutation of the di-leucine motif to alanine 
also led to lowered Ac-LDL internalisation.  
 
The motifs which control surface localization of SR-A are different although they also 
exist on the cytoplasmic domain. Six membrane proximal amino acids (after deletion 
of the first 49 amino acids) are sufficient for surface localization of SR-A. The 
cytoplasmic amino acid motif EDAD (residues 12 – 15) controls SR-A surface 
expression through interacting with the microtubule interacting protein Hook3 (Sano 
Figure 5.7 Sites regulating internalization and surface localization of SR-A. 
Summary of the various amino acid motifs on the cytoplasmic domain shown to be important 
for regulating receptor endocytosis and surface localization.   






et al., 2007), and modification of the EDAD amino acids to amine derivatives resulted 
in the reduced surface localization of SR-A. In the presence of the PI3K inhibitor 
wortmannin, SR-A surface localization is lowered, but this reduction is not seen in the 
amine derivative, showing that this process is regulated by the phosphatidylinositol-3 
kinase (PI3K) (Cholewa et al., 2010). Thus, PI3K could either directly or indirectly 
affect SR-A interaction with Hook3, hence affecting its surface localization. 
In our studies, we have observed that PI3 kinase inhibition by wortmannin also 
reduces the amount of SR-A on the cell surface, and that endocytosis of SR-A leads to 
enlarged SR-A positive endosomal structures. ADO was also capable of inhibiting 
phosphorylation of Akt at threonine 308 and serine 473, while it does not affect PDK-
1 activation (Figure 5.8). Akt is well-known to be an indicator of PI3K activity, as 
PI3K phosphorylation causes phosphatidylinositol-4,5-diphosphate to be converted to 
phosphatidylinositol-3,4,5-triphosphate, and this causes Akt to be recruited to the 
plasma membrane through its pleckstrin homology (PH) domain. PDK1 is also 
recruited to the plasma membrane via its PH domain, and it phosphorylates Akt on 
threonine 308. It is still unclear which kinase is responsible for phosphorylating serine 
473 (Cheng et al., 2005). We speculate that another pathway through which ADO 
affects surface localization of CD204 is the inhibition of PI3K. However, further work 
is required to confirm that ADO inhibits PI3K, the endosomal pathway through which 
PI3K acts to inhibit SR-A surface localization, and the manner in which PI3K 
regulates SR-A binding to Hook3. 
 






The effect of ADO on scavenger receptor surface expression does not only affect 
antigen presentation, it would also affect lipid uptake, as scavenger receptors are also 
involved in cholesterol uptake. The downregulation of surface scavenger receptors 
implies that ADO is likely to be efficacious in the treatment of atherosclerosis. During 
the initiation of atherosclerosis, low density lipoprotein is deposited in the 
subendothelial space, exposing them to modifications such as oxidation to form 
oxidized LDL (oxLDL). The presence of modified LDL leads to recruitment of 
monocytes into the arterial intima, where they differentiate into macrophages due to 
the presence of the colony stimulating factor (CSF). These macrophages express 
scavenger receptors, including CD204, CD36 and MARCO, which are known to be 
important receptors for binding and uptake of acetylated low density lipoproteins 
(acLDL), and oxidized LDL (oxLDL) to form foam cells. Foam cells are able to form 
atherosclerotic plaques and secrete pro-inflammatory factors, causing vascular 
remodeling and increasing the likelihood of thrombosis (Pluddemann et al., 2007; 
Badimon et al., 2011). ADO treatment would reduce surface scavenger receptor levels 
and hence lower overall uptake of oxLDL and formation of foam cells. This coupled 
with the inhibition of NF-κB activation in foam cells (Li & Li, 2011), decrease of the 
intercellular adhesion molecule 1 (ICAM-1), activation of NF-κB  (Chao et al., 2011) 
and induction of apoptosis in endothelial cells (Chen et al., 2004) would lower the 
likelihood of atherosclerotic plaques forming.  
 
Our results here demonstrate the inhibition of phagocytosis through downregulation of 
SR-A, which is a novel mechanism through which ADO may inhibit immune 
responses. SR-A downregulation is likely to be due to inhibition of its secretion by 






ADO. Further work is needed to elucidate the mechanism of how CD204 trafficking 
can be controlled by downstream signalling pathways. More work is needed to define 
the manner in which phosphorylation controls internalisation of CD204, as 
phosphorylation of serine at different locations result in different effects. In addition, 
the action of ADO on VAMP-8 in affecting CD204 secretion also needs to be 
elucidated. 
 







Figure 5.8 Andrographolide acts as a PI3 kinase inhibitor.  
A. Treatment of N9 microglia with wortmannin results in the formation of large CD204 positive 
endosomal structures. Cells were stained with anti-CD204 antibody for an hour, then allowed to 
endocytose at 37 °C for the timepoints indicated in the presence or absence of wortmannin. Scale bars 
are representative of 10 µm. 
B. Treatment of N9 microglia with ADO or wortmannin results in inhibition of AKT phosphorylation. 
Cells were treated with the drug indicated for 3 h before they were collected, lysed and analysed by 
western blot. 
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6. Conclusions and Future Directions 
6.1. Conclusions 
Our studies have shown that ADO is capable of downregulating surface receptors 
EGFR and scavenger receptors CD204 and CD36 in A-431 epidermoid carcinoma 
and N9 microglia respectively. This downregulation is mediated through receptor-
specific mechanisms and not through general endocytosis pathways. p38 MAPK 
activation induces EGFR internalisation through phosphorylation at serine 1046/1047, 
whereas ADO affects CD204 surface expression by inhibiting its secretion. We have 
also shown how ADO regulation of signaling molecules can in turn perturb receptor 
trafficking. This is a novel finding, as previous studies on ADO induced signaling 
focused mainly on the downstream effects on gene expression.  
 
6.2. Delving into additional drug mechanisms  
One important point that our study demonstrates is the need to understand how drugs 
affect cellular mechanisms. Drugs are usually used to target specific proteins, such as 
to inhibit enzyme or transcription factor activity. However, each drug molecule is also 
capable of inducing multi-faceted effects on the cell, particularly when they affect 
signaling pathways, which are responsible for controlling various cellular processes 
such as gene expression. Hence, while the search is ongoing for drugs targeting 
specific proteins, it is also important to expand our understanding of how existing 
drugs may affect intracellular processes, as these could contribute to the side effects 
of the drug in vivo. Such studies can also reveal previously undiscovered mechanisms, 
and lead to the development of known drugs for novel therapies.  






Cell surface receptors are the main conduits through which cells receive extracellular 
cues and initiate appropriate cellular responses. Thus, elucidating drug effect on 
receptor trafficking is critical to understanding the additional effects of a known drug. 
The most well-known mechanism of ADO is its ability to induce anti-inflammatory 
effects through inhibiting the NF-κB pathway. However, we have demonstrated here 
that it is also capable of inducing MAPK activation to affect EGFR trafficking. In a 
separate study on acetylsalicylic acid (ASA), which is a well-known pain reliever due 
to its inhibition of cyclooxygenase activity, EGFR and TfR was accumulated in the 
early sorting endosomes due to ASA enhancement on membrane recruitment of 
trafficking proteins sorting nexin 3 and 5 (Chiow et al., 2011). These effects on 
downregulating surface EGFR and TfR could explain the anti-cancer effects of ADO 
and ASA, as EGFR is a receptor that is upregulated in different forms of cancer, and 
TfR is important for cell survival through maintaining iron uptake. 
 
In order to study drug effect on receptor trafficking, it is important to have a good 
model which can allow for easy detection of minute changes. We have shown here 
that the A-431 cell line can be used as a model to detect drug-induced changes in 
receptor trafficking, and it can continue to be used in further studies of commonly 
used drugs to investigate previously undiscovered mechanisms (Tan et al., 2010; 
Chiow et al., 2011). A-431 offers a distinct advantage over other cell types as it 
expresses high levels of EGFR and TfR which can act as unique markers of the 
endocytic-degradation pathway and the endocytic-recycling pathway. Changes in 





receptor trafficking are also easily captured as it is an epidermal cell line, and it is 
easily imaged. 
 
6.3. Future Directions 
Many known drug with specific mechanisms have yet to be thoroughly investigated 
for its other effects on the cell. A recent trend in drug discovery is to relook at known 
pharmacophores for alternative uses in different diseases. One of the ways to achieve 
this is to gain a deeper understanding into the effects drugs may exert on the cell, 
specifically in the area of receptor trafficking. However, not all trafficking pathways 
of receptors have been fully characterised, unlike EGFR and TfR which have been 
very well-studied. Hence, it is necessary for us to expand our basic understanding of 
the various mechanisms which regulate specific receptor trafficking so that drugs 
targeting these mechanisms can be found. An example of this would be to further 
characterise mechanisms regulating CD204 surface localization, endocytosis and 
secretion, which is important, especially since CD204 mediates the uptake of many 
important molecules such as bacteria and lipoproteins. 
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8.1. Appendix I – Tables from Literature Review 
Table 8.1 Maximal plasma concentrations (Cmax) levels of differing treatments of 
ADO 
Maximum 
plasma levels of 
ADO 
Dosage; 
formulation; route of 
administration 
System Method of 
measurement 
Reference 
1.273 µg/ml (20 
mg/kg, oral, rats), 
3.00  µg/ml (200 
mg/kg, oral, rats) 
20mg/kg (intravenous), 
20 mg/kg, 200mg/kg 
(oral); Andrographis 
paniculata extract 










(Panossian et al., 
2000) 
393 ng/ml  20mg; Kan Jang tablets, 
daily; oral 
Humans 








(Chen et al., 
2007) 
4.14  µg/ml  10mg/kg; liposomal 
ADO; intravenous 
Rats HPLC, UV 
detection. 
(Suo et al., 2007) 
1.62 µg/ml 10mg/kg; powder tablet 
ADO; oral 






(Xu et al., 2009) 
1.42 µg/ml 1g/kg;  Andrographis 
paniculata aqueous 
extract; oral 
Rats HPLC, UV 
detection. 
(Akowuah et al., 
2009) 




(Maiti et al., 
2010) 9.64 µg/ml 25mg/kg; phospholipid-
ADO complex 
(herbasome); oral 
0.83 µg/ml 10mg/kg; ADO; oral Rats HPLC, UV 
detection. 
(Chellampillai & 
Pawar, 2011) 2.67 µg/ml 10mg/kg; ADO-
Eudragit® EPO 
complex; oral 














LPS stimulated RAW264.7 
macrophages 
iNOS upregulation suppressed (Chiou et al., 1998; 
Chiou et al., 2000) 
HL-60 derived neutrophils Inhibition of COX-2 expression (Hidalgo et al., 
2005) 
LPS stimulated mouse peritoneal 
macrophages 
Reduction of TNF-α and IL-12 via possible suppression of 
ERK phosphorylation 
(Qin et al., 2006) 
Human keratinocyte HaCaT cells 
induced with dead Propionibacterium 
acne 
Inhibition of IL-8 and TNF-α secretion. (Fu et al., 2011) 
Human whole blood Reduction of pro-inflammatory cytokines TNF-α, IL-6, IL-1β 
and anti-inflammatory cytokine IL-10 due to downregulation of 
mRNA expression (except for IL-1β) 
(Parichatikanond et 
al., 2010) 
PMA/ Ionomycin stimulated Jurkat T 
cells  
Reduction of IL-2 production via NFAT inhibition  (Carretta et al., 
2009) 
LPS, TNF-α, PMA induced 
HUVECS, macrophages, pulmonary 
vascular endothelial cells (PVECS) 
Reduction in tissue factor (TF) mRNA and protein expression 
levels and TF activity through inhibition of p50 binding to TF 
promoter. 
(Li et al., 2009) 
LPS stimulated J774A.1 
macrophages; 
Reduction of NO, PGE2, IL-1β, IL-6 production (Chandrasekaran et 
al., 2011) 
A23187 differentiated HL-60 
promyelocytic leukaemia cells 








fMLP stimulated peripheral human 
neutrophils 
Reduced neutrophil adhesion and transmigration (Shen et al., 2002) 
C5a, MIP1-α stimulated RAW264.7 
macrophages,  
Reduction of chemotactic migration via inhibition of PI3K and 
suppression of MEK1/2. 
(Tsai et al., 2004) 
HL-60 binding to TNF-α induced 
human endothelial cell lines 
EA.hy926; HUVEC 
Inhibition of TNF-α induced expression of ICAM-1 on 
endothelial cells leading to decreased monocyte adhesion  
(Habtemariam 1997, 
(Yu et al., 2010; 
Chen et al., 2011)  












LPS, IL-4 activated macrophages Reduction of macrophage activation by both LPS and IL-4, 
decrease in cell surface MHC class I, CD40, CD80, CD86, 
CD206;  
(Wang et al., 2010a) 
PAF induced HL-60 derived 
neutrophils; LPS stimulated mouse 
MLE-12 cells;  TNF stimulated 293T 
embryonic kidney cells;  
 
Inhibition of NF-κB activation  
 
(Xia et al., 2004; 
Hidalgo et al., 2005; 
Iruretagoyena et al., 
2006) 
Human platelet cell suspension; 
human whole blood  
Inhibition of COX-1 and COX-2 activities (Parichatikanond et 
al., 2010) 
Mixed lymphocyte reaction from 
lymph node cell suspensions 
Reduction of T cell activation through inhibition of antigen 
processing and DC maturation 
(Iruretagoyena et al., 
2005; Iruretagoyena 
et al., 2006) 
LPS induced ventral mesencephalic 
microglia culture; BV-2 microglia 
Protection against LPS induced neurotoxicity and activation 
leading to reduced levels of superoxide, TNF-α, ntric oxide, 
PGE2; mRNA expression of COX-2 & TNF-α reduced, with 
reduction in COX-2 protein stability. 
(Wang et al., 2004) 
CD4+ T cells isolated from 
haemophilic mice co-cultured with 
dendritic cells pulsed with canine 
FVIII 
Increase in T cell secretion of immunosuppressive cytokines 
IL-10, TGF-β. 
(Qadura et al., 2008) 
LPS & IFN-γ stimulated rat primary 






Suppression of iNOS and MMP-9 expression, reduced NF-κB 




(Hsieh et al., 2010) 








Cellular System Specific effect Reference 
Induction of 
apoptosis 
Human primary rheumatoid arthritis 
fibroblast-like synoviocytes 
Induction of cell cycle arrest at G0/G1 phase, induction of 
apoptosis due to increase in expression of pro-apoptotic 
molecule Bax, release of cytochrome c and the corresponding 
increase of cleaved caspase 3. 




PAF induced human blood platelets Inhibition of platelet aggregation (Amroyan et al., 
1999) 
Thrombin induced rat platelets  Inhibition of platelet aggregation through downregulation of 
ERK2 phosphorylation 
(Thisoda et al., 
2006) 
Arachidonic acid, collagen or 
thrombin induced human platelets 
Inhibition of collagen induced platelet aggregation through 
activation of eNOS-cyclic GMP pathway and inhibition of the 
PI3K-Akt-p38 MAPK, PLC-γ2-DAG-PKC pathway. 
(Lu et al., 2011) 
Table 8.2 Anti-inflammatory effects of ADO in vitro. 
  





System Effect of ADO Reference 
Mouse model of acute peritonitis 
induced by TNF-α, IL1-β, LPS 
Reduced peritoneal leukocyte infiltration due to reduction in E-selectin 
expression on stimulated endothelial cells  
(Xia et al., 2004) 
Mouse model of septic shock induced by 
LPS 
Increased mouse survival (Xia et al., 2004) 
Asthma mouse model induced by OVA 
sensitization.  
Inhibition of ovalbumin induced asthma via inhibiting IKK β (Xia et al., 2004; Bao et al., 
2009) 
Mouse model of EAE induced by 
injection of myelin oligodendrocyte 
glycoprotein derived peptide 
Reduction of EAE severity due to diminished antimyelin T cell and antibody 
response, as well as upregulation of myelin specific Fox3p regulatory T cells 
(Iruretagoyena et al., 2005; 
Iruretagoyena et al., 2006) 
Mice induced with OVA and Freund’s 
adjuvant  
Decreased level of delayed type hypersensitivity reaction  (Iruretagoyena et al., 2005) 
Carageenan induced paw oedema  Antiedematogenic activities, reduced paw swelling. (Sheeja et al., 2006; 
Suebsasana et al., 2009; 
Sulaiman et al., 2010) 
Mouse models of pain: acetic acid 
induced writhing; hot plate test. 
 
Antinociceptive activities: reduced nociception through a non-opoid mechanism. 
 
(Sulaiman et al., 2010) 
Hemophilic mice infused with immature 
dendritic cells pulsed with canine FVIII 
(cFVIII) treated with or without ADO 
Decrease in FVIII inhibitors, no change in CD4+Foxp3+ regulatory T cells.  (Qadura et al., 2008) 
Rat model of permanent cerebral 
ischaemia 
Reduced infarct volume, decrease in OX-42 activated microglia, pro-
inflammatory cytokines IL-1β, TNF-α & PGE2, reduced NF-κB nuclear 
translocation. 
(Chan et al., 2010) 
Mouse model of arterial ligation; rat 
model of autografting veins 
Reduction in neointima hyperplasia and reduction in neointima to media ratio; 
reduction in E-selectin, NF-κB p65, MMP-9, VCAM-1, tissue factor mRNA and 
protein expression.  
(Wang et al., 2007; Zhi-
Tao et al., 2011) 
Mice primed with Hepatitis B antigen Reduction in antibody production (Wang et al., 2010a) 
Mouse model of deep vein thrombosis Reduction of venous thrombosis through reducing tissue factor expression (Li et al., 2009) 
Mouse model of sodium induced 
microthrombi 
Longer time of veseel occlusion, lowered mortality rates (Lu et al., 2011) 
Table 8.3 Anti-inflammatory effects of ADO in vivo. 
 





Type of drug; dosage Effect of drug Reference 
Immunoguard® (Andrographis 
paniculata; Eleutherococcus 
senticosus; Schizandra chinensis; 
Glycyrrhiza glabra); 48mg 
ADO/day 
 Decrease in duration, frequency and severity of attacks in familial 
meditarranean fever (FMF) 
 Increases nitric oxide levels and decreases IL-6 in FMF patients 
(Amaryan et al., 2003; 
Panossian et al., 2003) 
Kan Jang (Andrographis paniculata, 
Eleutherococcus senticosus) or 
Andrographis paniculata dried 
extract (Caceres et al.); 60mg 
ADO/day or 1200 mg /day of 
extract; target group: adults 
 Symptoms in upper respiratory tract infections were markedly 
improved – sore throat, dryness in throat; headache; nasal symptoms, 
malaise. 
 Similar symptoms in sinusitis groups and common cold were relieved 
by Kan Jang. 
 Recovery at a faster, rate, reduction in number of days of sick leave. 
(Caceres et al., 1999; 
Melchior et al., 2000; 
Gabrielian et al., 2002; 
Kulichenko et al., 2003)  
Kan Jang (Andrographis paniculata, 
Eleutherococcus senticosus); 30mg 
ADO/day; target group: children 
 Recovery from uncomplicated common cold at a faster rate 
 Reduction in nasal secretion and nasal congestion. 
(Spasov et al., 2004) 
Paractin ® (Andrographis 
paniculata) 30mg ADO 3 times/ 
day ) 
 Reduction of grade and number of swollen and tender joints in 
rheumatoid arthritis patients. 
 Reduction of rheumatoid factor, IgA, IgM levels in blood. 
(Burgos et al., 2009) 
Table 8.4 Anti-inflammatory effects of ADO or Andrographis paniculata in humans 
  





Type of drug; dosage; route System Effect of drug Reference 
ADO and ethanol extract of A. 
paniculata (APE); APE: 25mg/kg, 
oral; ADO: 1 mg/kg, oral or 
4mg/kg, intra-peritoneal. 
Balb/c mice 
immunized with red 
blood cells (RBC) 
Increase in RBC specific antibody titres, increase in 
haemolytic plaque forming cells,  increase in delayed 
type hypersensitivity 
(Puri et al., 1993) 
ADO (PN355); 5mg/kg for 3 weeks 
and 10mg/ kg for 3 weeks; oral 
HIV positive 
patients 
Increase in number of CD4+ lymphocytes in HIV 
positive patients. 
(Calabrese et al., 
2000) 
ADO and Kan Jang (Andrographis 
paniculata,  Eleutherococcus 
senticosus); 2µM to 10 µM; in vitro 
Human peripheral 
blood lymphocytes 
Proliferation of PHA induced leukocytes: 
ADO: 5% increase; Kan Jang: 16.4% decrease;  
 
Cytokine and immune activation markers (without 
PHA): 
ADO: IFN- γ increase 23.3%, Neopterin increase 
22.2%,  β2MG increase 270%.   
Kan Jang:  IFN- γ increase 20.9%; Neopterin 
increase 16.7%; β2MG increase 310%. 
 
Cytokine and immune activation markers (with 
PHA): 
 
ADO: TNF-α increase 22.6%, β2MG increase 
82.4%.   
Kan Jang:   TNF-α increase 1091%, β2MG increase 
138%. 




deoxy-andrographolide; 0 – 100 µM 





Increase in lymphocyte proliferation and IL-2 
secretion.  
(Kumar et al., 
2004) 
    





Table 8.5 Immunostimulatory effects of ADO or Andrographis paniculata  
 
Mechanism Type of drug; 
dosage; route 







aqueous extract of A. 
paniculata; various 
concentrations for 48 
h; in vitro. 
Colon, breast, CNS, lung, 
melanoma, prostate, ovarian and 
renal cancer cell lines. 
ADO: inhibits all types of cancer cell lines; 
Methanol, petroleum ether, dichloromethane 




ADO and 25 
analogues;  
Colon, breast, CNS, lung, prostate, 
ovarian and renal cancer cell lines. 










ADO MCF-7 (hormone dependent) and 
MDA-MB-231 (hormone 
independent) breast cancer cells, in 
vivo MCF-7 tumour xenograft. 
Induction of cell cycle arrest at G1 phase, 
inhibition of in vivo tumour growth.  
(Stanslas et 
al., 2001a) 
Type of drug; dosage; route System Effect of drug Reference 
ADO and ethanol extract of A. 
paniculata (APE); 1mg/kg or 
4mg/kg ADO; 25mg/kg or 50mg/kg 
(APE) fed for 14 or 28 days; oral 
gavage 







Serum IgG levels for ADO and APE treatment: 
increase   approximately 400%;  
 
IFN-γ secretion by splenocytes: increase 700 % 
(APE); increase 800 % (ADO) 
(Xu et al., 2007) 
Andrographolide; 15-30 µM for 24 





Increased MIF synthesis and secretion through 
induction of reactive oxygen species 
(Cho et al., 2009) 





ADO Various cancer cell lines Induction of cell cycle arrest at G0/G1 phase  (Rajagopal et 
al., 2003) 
ADO, DRF3188; 5 – 
25 µM for 24 or 48 h; 
in vitro 
MCF-7 breast cancer cells Induction of cell cycle arrest at G0/G1 due to 
upregulation of p27, and decrease in Cdk4 
(ADO, DRF3188), decrease in Cdk 1 (ADO) 
(Satyanaraya
na et al., 
2004) 
ADO, DRF3188; 0 – 
100 mg/kg (ADO), 0 
– 50 mg/kg 
(DRF3188); intra-
peritoneal.  
MCF-7-hollow fibre assay 
implanted in peritoneum (IP) and 
subcutaneous (SC) sites of Swiss 
Albino mice 
Decrease in proliferation (IP and SC); 
upregulation of p27 and decrease in Cdk4 (IP) 
(ADO, DRF3188). 
ADO, ethanol extract 




HL-60 human promyelocytic 
leukaemia cells, KB epidermoid 
carcinoma cells, H4-II-E hepatoma 
cells, CNE3 human nasoxpharynx 
cells.  
ADO and APE inhibit all types of cancer cell 
growth; induction of G0/G1 phase arrest and 
mitochondria-dependent pathway of apoptosis. 
(Cheung et 
al., 2005) 
ADO; 0 – 30 µM; in 
vitro 
Human colorectal carcinoma Lovo 
cells 
Inhibition of cell growth, G1 arrest, decrease in 
cyclin A/Cdk 2 & cyclin D/Cdk 4 complex, 
upregulation of p21 & p16; phosphorylation of 
p53, increase in Rb/E2F complex.  
(Shi et al., 
2008) 




MCF-7 breast cancer cells, HCT-
116 colon cancer cells, National 
Cancer Institute cancer cell line 
screen 
Inhibition of growth, induction of G1 arrest, and 
apoptosis. SRJ9 downregulated CDK4 but not 
CDK1. 
 




ADO, 0 – 150 µM for 
24 – 72 h, in vitro. 
HepG2 human hepatoma cells Decrease in cell viability with IC50 40.2µM for 
48 h, G2/M cell cycle arrest, induction of 
apoptosis with caspase-3 activation and loss of 
(Li et al., 
2007) 





mitochondria membrane potential. 
Increase in Bax, phosphorylated cdc2, p53 
expression. 
Increase in amount of H2O2, decrease in 
superoxide radicals, decrease in GSH, increase in 
SOD activity 
ADO, 35 µg/ml for 1- 
12 h, in vitro. 
Human prostatic adenocarcnima 
PC-3 cells 
Induction of apoptosis: change in morphological 
characteristics, activation of caspase-3 and 
caspase-8. 
(Kim et al., 
2005) 
ADO, 0 – 100 µM, 24 
h, in vitro. 
HepG2 human hepatoma cells, 
Hela human cervical cancer cell 
line, MDA-MB-231 human breast 
cancer cell line 
Induction of apoptosis: caspase-8 and -9, 
cleavage of Bid, conformational change in Bax 
and increase in Bax mitochondrial translocation 
leading to cytochrome c release. 
(Zhou et al., 
2006) 
ADO, 0 – 1.4mM, 24 
– 72 h, in vitro. 
TD47 human breast cancer cells 
 
 
Reduction of cell viability, induction of 
apoptosis: increase in Bax and p53, reduction in 
Bcl-2 expression. 
(Sukardiman 
et al., 2007) 
ADO, 0 – 90 µM, 2 – 
24 h, in vitro. 
HepG2 and Hep3B human liver 
cancer cells, Hela human cervical 
cancer cells, HCT116 human 
colorectal cancer cells treated with 
or without TRAIL 
Reduction of cell viability, induction of 
apoptosis: PARP cleavage, induction of caspase-
8 apoptosis pathway, increased expression of 
DR4, increased p53 due to increased 
stabilization, increased p21 expression, JNK 
activation. 
(Zhou et al., 
2008) 
ADO, 0 – 100 µM for 
up to 96 h, in vitro. 
Promyelocytic leukaemia cell lines 
HL-60, NB-4 and all-trans retinoic 
acid resistant NB4-R2 
Growth inhibition of leukaemia cell lines, 
induction of differentiation to mature 
granulocytes, induction of apoptosis – membrane 





ADO, 0 – 200 µg/ml 
for 24 – 48 h, in vitro. 
SMMC-7721 human hepatocellular 
carcinoma treated with or without 
5-fluorouracil 
Inhibition of cellular proliferation, induction of 
apoptosis: change in Bax conformation, 
induction of caspase-8 apoptosis pathway, 
upregulation of p53 expression.  
(Yang et al., 
2009b) 





ADO, 0 – 200 µM for 
48 h, in vitro. 
PC-3 prostate cancer cells IC50: 23.3 µM; induction of apoptosis: 
upregulation of Bax and downregulation of Bcl-
2, activation of caspase-3 and decrease in VEGF 
production. 
(Zhao et al., 
2008) 
ADO, 0 – 100 µM for 
24h or 48 h, in vitro. 
Ramos p53-mutated Burkitt 
lymphoma; SUDHL4 diffuse large 
B cell  lymphoma (DLBCL); HF-1 
follicular lymphoma (FL), Granta 
mantle cell lymphoma (MCL);  
patient samples for DLBLC, FL, 
MCL. 
Decrease in cell viability, increase in ROS, 
induction of apoptosis: activation of caspase 3, 8 
and 9, cleavage of Bid and PARP, 
conformational change in Bax and Bax 
mitochondrial translocation. 
(Yang et al., 
2010) 
ADO, 0 – 100 µM for 
48 h, in vitro 
Multiple myeloma cancer stem cell 
in 2-D cell culture or with human 
bone marrow stromal in 3-D cell 
culture 
Decrease in cell viability, induction of apoptosis: 
Annexin V positive, activation of caspase 3/7, 8 
and 9. 
(Gunn et al., 
2011) 
ADO, 0 – 50 µM for 
0 – 48 h, in vitro. 
Hep3B, HepG2 human hepatoma 
cells. 
Decrease in cell viability, reduction in colony 
forming units, induction of apoptosis: DNA 
fragmentation; reduction in cellular glutathione, 
activation of JNK and p38 and activation of JNK 
signalling cascade in presence of BSO.  
(Ji et al., 
2011) 
ADO, 10mg/kg once 
daily for 16 days, 
intra-peritoneal. 
Hep3B cells xenografted onto nude 
mice 
Decrease in tumour volume and approximately 





ADO, 0 – 15 µM for 
up to 18h, in vitro. 
HepG2 human hepatoma cells, 
HCT116 human colorectal cancer 
cells, Hela human cervical cancer 
cell line, MDA-MB-231 human 
breast cancer cell line treated with 
or without doxorubicin 
Suppression of constitutive and IL-6 induced 
STAT3 activation, IL-6 induced nuclear 
translocation, suppression of JAK1/2 activation, 
sensitization to doxorubicin induced 
cytotoxicity.  
(Zhou et al., 
2010) 
ADO, 0 – 20 µM for 
24 – 48 h, in vitro. 
LNCaP, DU145, PC-3 prostate 
cancer cells 
Inhibition of IL-6 expression, IL-6 induced 
signalling, inhibition of cell viability and 
(Chun et al., 





induction of apoptosis. 2010) 
ADO, 4mg/kg every 2 
days for 8 weeks, 
intra-peritoneal 
DU145 xenografted nude mice 
prostate cancer model 
 
 
Suppression of tumour growth 
ADO, 0 – 30 µM, 0 – 
96 h, in vitro. 
H-ras transformed rat kidney 
epithelial cell line with or without 
radiation, SW480 human colon 
cancer cells 
Sensitization of Ras-trasformed cells to 
radiation, decrease of Akt activation, inhibition 
of radiation-induced NF-κB activity. 
(Hung et al., 
2010) 
ADO, 300 mg/kg, 
subcutaneous and 
peritumour injection 
Male nude mice subcutaneously 
injected with Ras-transformed cells 
Increase in tumour growth delay 
ADO, 0 – 40 µM for 
6 – 24 h, in vitro. 
C4-2, CWR22Rv1 and LNCaP, 
prostate cancer cells. 
Inhibition of AR synthesis and expression, 
inhibits downstream transcription of PSA, 
nuclear translocation of AR leading to apoptosis 
and inhibition of cell growth; inhibition of AR 
binding to Hsp90. 
(Liu et al., 
2011) 
ADO, 6.2 µg/ml 
twice/ week for 5 
weeks, intra-
peritoneal. 
Hamster buccal pouch model of 
squamous cell carcinogenesis 
Decreased tumour volume, cell proliferation and 
tumour vascularisation, increased apoptosis, 
inhibition of NF-κB activation.  
(Wang et al., 
2011) 
ADO, 0 – 200 µM for 
24 to 72 h, in vitro. 
Tb human tongue carcinoma cells Reduction of cell viability, induction of 
apoptosis and G2/M arrest through decrease in 
NF-κB activation and drop in p65, c-Myc and 
cyclin D1 expression.  
Inhibition 
of migration 
ADO, 0 – 50 µM for 





Lowered cancer cell adhesion to endothelial cells 
through inhibition of TNF-α induced E-selectin 
expression on endothelial cells and decrease of 
sle
x
 expression on gastric cancer cells.  
(Jiang et al., 
2007) 
ADO, 0 – 5 µM for 
24 h, in vitro. 
Temperature sensitive v-Src 
transformed RK3E rat kidney 
Inhibited v-Src induced morphological 
transformation, downregulation of E-Cadherin, 
(Liang et al., 









actin filament disorganization and ERK1/2 
phosphorylation. This is due to cellular decrease 
in tyrosine phosphorylation, because of 
downregulation of v-src expression due to 
increased degradation from increased 
ubiquitination.  
2008) 
ADO, 0 – 5 µM for 
24 h, in vitro. 
Lovo human colorectal carcinoma 
cells 
Inhibition of motility and invasion, through 
decrease in MMP-7 activity, expression and 
synthesis, AP-1 DNA binding reduced.  
(Shi et al., 
2009) 
ADO, 1 – 10 µM for 
24 h, in vitro. 
CT26, HT29 human colon cancer 
cells 
Decrease in invasion ability, inhibition of MMP-
2 activity but not expression, attenuation of 
ERK1/2 signalling. 
(Chao et al., 
2010a) 
ADO, 0 – 5 µM for 
24 h, in vitro. 
A549 non small cell lung cancer 
cells 
Decreased motility and invasion, decrease in 
MMP-7 activity and synthesis due to inhibition 
of PI3K signalling leading to decreased AP-1 
DNA binding. 





Ethanol extract of A. 
paniculata, 
10mg/dose/animal, 
for 10 days ; ADO, 
500 µg/dose/animal; 
for 10 days.  
EL4 thymoma cells inoculated into 





Increase in mice survival time, increase in IL-2 




Ethanol extract of A. 
paniculata (APE), 
10mg/dose/animal, 
for 5 days; ADO, 500 
µg/dose/animal; for 5 
days. 
Balb/c mice injected peritoneally 
with Ehrlich ascites carcinoma 
(EAC). 
Increase in natural killer cell activity, antibody 
dependent cell cytotoxicity, antibody dependent 
complement mediated cytotoxicity, proliferation 
in the presence of mitogens – splenocytes, 
thymocytes and bone marrow derived cells  for 





Ethanol extract of A. 
paniculata (APE), 
DLA Dalton’s lymphoma ascites 
cells injected into right hind limb of 
Increase in total white blood cell count, decrease 
in tumour volume, increase in IL-2, GM-CSF, 
(Sheeja & 
Kuttan, 2008) 












for 30 minutes), or 
radiation 
(4Gy/animal). 




ADO, 0 – 2.4 mg/ml 
for 1 to 5 days, in 
vitro. 
Multidrug resistant HCT-8 
colorectal cancer cells treated with 
5-FU, ADM and DDP 
Increased cell growth inhibition and increase in 
apoptosis, possibly due to lower expression of 
efflux glycoprotein P-170. 
(Han et al., 
2005) 
ADO (0 – 5 µM) for 
up to 1 h. 
A549, H1355, H1299, CL1-0, CL1-
5 non small cell lung cancer cell 
lines 
Inhibition of TGF-β signalling resulting in 
increased PHD2, causing increased proteolytic 
degradation of HIF-1α, leading to decrease in 
VEGF signalling. 
(Lin et al., 
2011) 
Table 8.6 Anti-cancer effects of ADO or Andrographis paniculata  
 





8.2. Appendix II – Buffer Preparation 
Cell culture media (500ml) 
450 or 425 ml   High glucose Dulbecco’s modified eagle medium (DMEM) 
50 ml or 25 ml Fetal bovine serum (FBS) [for 10% or 5% complete medium] 
5ml   100X Antibiotics-antimycotics 
5ml   10mM MEM Non-essential amino acids 
5ml   200mM L-glutamine 
2.5ml  1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer 
For serum-free media, the components are similar, with the exception that no FBS is 
added, and 500ml of DMEM is used.  
 
Immunofluorescence buffers 
Permeabilization buffer (100 ml) 
0.1 g   Saponin powder 












Western Blot Gel composition 
Resolving gel (10 mL): 
 8% 10% 12% 
H2O 5.3 mL 4.8 mL 4.3 mL 
Acrylamide/bisacylamide (40%, ratio 19:1) 2 mL 2.5 mL 3 mL 
1.5 M Tris-HCl pH8.8 2.5mL 
10% SDS (w/v) 100 µL 
10% APS (w/v) 100 µL  
TEMED 8 µL 
 
5 % Stacking gel (1ml) 
730 µL  H2O 
125 µL  Acrylamide/bisacylamide (40%, ratio 19:1) 
125 µL  1 M Tris-HCl pH 6.8 
10 µL   10% SDS (w/v) 
10 µL   10% APS (w/v) 
1 µL   TEMED 
 
Western Blot Buffers 
5x SDS Loading Buffer 
12.5 mL of 1 M stock  Tris-HCl pH 6.8 
5 g    SDS 
0.25 g    Bromophenol blue 
29 mL of 87 % stock  Glycerol 
5 % (v/v)   β-mercaptoethanol 
Top up to 50 mL with distilled water 
 
  





10x Tris Glycine Buffer (5 L) 
30.2g  Tris Base 
188g  Glycine 
Top up to 1 L with distilled water 
 
SDS-PAGE Running Buffer (2 L) 
200 ml  10x Tris glycine buffer 
20 ml   10% SDS 
Top up to 2 L with distilled water 
 
Transfer Buffer (2 L) 
200 ml  10x Tris glycine buffer 
400 ml  Methanol 
Top up to 2 L with distilled water 
 
Blocking Buffer (100 ml) 
100 ml  0.1% PBS-Tween 20 (PBST) 
5 g   Skim milk powder 
  
Western Blot Lysis Buffer (1 ml) 
900 µl  1 X autoclaved PBS 
100 µl  10 % Triton X-100 
20 µl  100mM PMSF 
20 µl  2X Roche complete protease inhibitor EDTA-free 
 
